



Vaccines and Global Health: The Week in Review
11 December 2021 :: Issue 636
Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted and the elements of each edition are presented as a set of blog posts at <https://centerforvaccineethicsandpolicy.net>. This blog allows full text searching of over 23,000 entries.

Comments and suggestions should be directed to

*David R. Curry, MS
Editor and
Executive Director
Center for Vaccine Ethics & Policy
david.r.curry@centerforvaccineethicsandpolicy.org*

Request email delivery of the pdf: If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.

Contents

- :: [Milestones - Perspectives](#)
- :: [Coronavirus \[COVID-19\] - WHO](#)
- :: [Emergencies](#)
- :: [Organization Announcements](#)
- :: [Journal Watch](#)

Milestones - Perspectives

:::::

:::::

State of inequality: HIV, tuberculosis and malaria

WHO

Published 2021 :: 260 pages

PDF: [English](#)

Foreword

...Although great strides have been made to expand health services and prevention efforts across the three diseases, progress to date has not been fast enough. The COVID-19 pandemic has disrupted essential health services in many countries, jeopardizing the gains we have made.

HIV, TB and malaria continue to take a disproportionately large toll on the poorest, least educated and most rural parts of society. Certain communities – including sexual and gender minorities, sex workers, people in prisons, people who inject drugs, migrants, refugees, displaced people and indigenous people – face stigma and discrimination, resulting in lower service access and higher disease risk. COVID-19 has further exposed these fault lines.

The World Health Organization and the Global Fund to Fight AIDS, Tuberculosis and Malaria are part of a group of agencies working together to accelerate progress towards the health-related SDGs through the Global Action Plan for Healthy Lives and Well-being for All. Understanding patterns of inequalities in these diseases is essential for taking strategic, evidence-informed action to realize our shared vision of ending the epidemics of HIV, TB and malaria.

This report presents the first comprehensive analysis of the magnitude and patterns of socioeconomic, demographic and geographic inequalities in disease burden and access to services for prevention and treatment....

Conclusions

The COVID-19 pandemic has had far-reaching and devastating impacts on health and health systems worldwide. Against the backdrop of the COVID-19 pandemic, the quality and availability of essential care for all conditions, including HIV, TB and malaria, have been compromised. Testing, treatment and prevention programmes have suffered widespread interruptions, and many people have faced changes in routine services and heightened stigma, discrimination and fear. Tackling inequities in HIV, TB and malaria is key to accelerating progress and closing the persistent gaps in access to care and health outcomes across population subgroups.

Identifying and characterizing inequalities through health inequality monitoring lends important insights to inform differentiation in service provision, so that resources are aligned to achieve maximal impact. An understanding of patterns of inequalities can help to promote equity by increasing the availability of essential health services and interventions among groups at higher risk of infection or mortality.

Recognizing instances where countries have reduced inequities to improve access to key services among groups experiencing higher burden of disease provides an important opportunity to dig deeper into understanding how and why actions were successful. The results of health inequality monitoring,

alongside consideration of relevant in-depth quantitative and qualitative studies, can be used to inform equity-oriented policies, programmes and practices, which are central to address the underlying conditions that put groups at higher risk for HIV, TB and malaria.

The impact of monitoring activities, however, lies in their application. Developing technical capacity for health inequality monitoring is important to ensure the process is rigorous and impactful and generates change. Capacity-building activities may encompass identifying and implementing changes to data sources to strengthen the data available for inequality monitoring. To ensure the representation of all groups, data collection efforts should take into account subnational and civil society programmes that work with disadvantaged groups. Other activities include conducting training and skills-building sessions for data analysis and for conducting quantitative and qualitative studies; and strengthening reporting approaches to effectively reach diverse target audiences.

Importantly, there is a need to support activities and practices that translate the findings of inequality analyses to inform the development of policies and programmes and to empower the wider use of data. WHO has developed a number of tools and resources to support health inequality monitoring (see <https://www.who.int/data/gho/health-equity>).

Media Release

WHO and Global Fund Warn Inequalities Block Progress Towards Ending AIDS, TB and Malaria

09 December 2021

GENEVA – Inequities have been widely acknowledged as barriers to achieving global and national goals and targets in HIV, TB and malaria programs. However, the magnitude and extent of underlying health inequalities have remained poorly documented and understood.

Until those inequalities are better identified, and their consequences better understood, it will be hard for programs to meet people's real health needs. Now, for the first time, a new report from the World Health Organization and the Global Fund to Fight AIDS, Tuberculosis and Malaria systematically assesses the global an important step forward in understanding how inequalities are hindering the fight against the three diseases. Using the latest available global data for 32 health indicators in up to 186 countries, it shows that while national averages of HIV, TB and malaria indicators have generally improved in the past decade, the poorest, least educated and rural subgroups tend to remain at a disadvantage across most HIV, TB and malaria indicators...

:::::
:::::

Joint Statement: Foundations Decry Vaccine Inequity Leading to the Emergence and Circulation of Dangerous Variants

12.01.21

NEW YORK — As concern escalates over the threat of the Omicron Covid-19 variant spreading, a group of the world's leading philanthropies have joined together to call on G7 countries and multinational pharmaceutical companies to urgently lift their restrictions on vaccine supply.

The [Global Alliance of Foundations](#) calls on G7 countries under the U.K. and incoming German leadership to make good on earlier commitments and aim even higher to ensure that countries in the Global South have the means to buy, administer, and quickly produce their own vaccines.

We also urge countries to refrain from imposing unreasonable travel bans that penalize countries that shared early warnings about this new variant in the name of global health security.

This new variant comes as the world is failing to meet the World Health Organization's goal of [vaccinating 40 percent](#) of every country's population by the end of 2021. Less than 7 percent of Africa's population is fully vaccinated, and the global death toll has exceeded [five million](#) and continues to climb.

The longer the world takes to deliver vaccine equity, the more we allow Covid-19 to mutate and become more dangerous. This new variant demonstrates that vaccine nationalism is a short-sighted approach that is self-defeating and puts us all at risk. It reinforces the reality, once again, that no one is safe until everyone is safe.

While the world awaits more information on whether existing vaccines will be effective against the new variant, we will no doubt see additional pressure on vaccine supplies. Global leaders must do everything in their power to accelerate sharing of intellectual property and technology transfer to allow additional manufacturers to reproduce Covid-19 vaccines in low- and middle-income countries.

Along with the African Vaccine Acquisition Trust (AVAT), the Africa Centres for Disease Control and Prevention, and COVAX, we call for countries with excess doses to stop hoarding and donate those supplies now, and to continue to donate future excesses in real-time. Donations to COVAX, AVAT, and African countries must be made in a way that allows their governments to mobilize their resources in support of equitable distribution and enables both short- and long-term planning.

Covid-19 is not a one-off emergency. This variant will be followed by others, and by new pandemics. This brings home the need for structural global pandemic preparedness and response; effective surveillance and global early warning systems for emerging diseases and new variants; an upscale in local systems' delivery capacity; medicines manufacturing capacity taken out of the hands of the few and expanded to each continent; global responses based on solidarity, equity, and the understanding of mutual interest; and adequate financing to support all countries in effective response.

We must do better. If we are to address collective global crises, whether Covid, climate, or economic recovery, we need ambitious and urgent reform of the multilateral architecture, including an emphasis on strengthening localized capacity and resilience to deliver a just, green, and inclusive recovery.

James Holt, Executive Director, Archewell Foundation

Kate Hampton, CEO, Children's Investment Fund Foundation

Peter Laugharn, President, Conrad N. Hilton Foundation

Darren Walker, President, Ford Foundation

Boichoko Dithlake, Head, Civil Society Support, Kagiso Trust

Mo Ibrahim, Founder and Chair, Mo Ibrahim Foundation

Mark Malloch-Brown, President, Open Society Foundations

Dr. Rajiv J. Shah, President, The Rockefeller Foundation

:::::

:::::

World Medical Association [to 11 Dec 2021]
<https://www.wma.net/news-press/press-releases/>

Press Releases

Global Physicians Condemn Continuing Vaccine Inequity

2nd December 2021

Global physician leaders have condemned the continuing inequity of vaccine distribution.

Following the emergence of the new Omicron variant, the World Medical Association has strongly criticised wealthier nations for not doing enough to help lower income countries to vaccinate their populations.

WMA President Dr. Heidi Stensmyren said: 'This blatant inequity amounts to a failure of global leadership and is deeply disappointing. Until we all learn that this pandemic cannot be contained by one country alone, we will all continue to suffer.

'The WMA fully supports the World Health Organisation in its latest plan to develop an instrument for pandemic prevention, preparedness and response with a whole-of-government and whole-of-society approach, prioritizing the need for equity. But for coping with the current pandemic, this comes too late.

'Developed countries must now do more to embrace international cooperation. We must progress together not separately and this cannot wait for a new treaty to be finished. We cannot afford to leave anyone behind'.

:::::

:::::

UNICEF and WHO, in partnership with Gavi, ask Ted Chaiban to serve as Global Lead Coordinator for COVID Vaccine Country Readiness and Delivery

Statement

NEW YORK, 6 December 2021 – "I am pleased to announce that UNICEF and WHO, in partnership with Gavi, have asked Ted Chaiban, currently UNICEF Regional Director Middle East and North Africa, to serve as Global Lead Coordinator for COVID Vaccine Country Readiness and Delivery.

"This decision is an expression of our joint commitment to reinvigorate efforts to turn vaccines into vaccinations in low- and middle-income countries.

"With vastly improved supply, the world no longer has a global vaccine supply problem; it has a vaccine equity and delivery problem. More than 80 per cent of the world's vaccines have gone to G20 countries while millions of people, including healthcare workers, in low-income countries are still unprotected.

"As vaccine doses become increasingly available in the coming weeks, it is critical that countries are prepared, resourced and able to roll them out.

"With support from COVAX, the African Union, AVAT and other partners, governments in low-income countries have made important progress in getting ready to receive and administer COVID-19 vaccines at a scale sufficient to meet global objectives. However, they still face significant challenges in scaling up capacity....

:::::

:::::

Global Health Security (GHS) Index 2021 | Advancing Collective Action and Accountability Amid Global Crisis

Authors: Jessica A. Bell; Jennifer B. Nuzzo; Nellie Bristol; Gabrielle Essix; Christopher Isaac; Amanda Kobokovich; Diane Meyer; Lucia Mullen; Sophie Rose

Date posted: December 08, 2021

Publication type: Report 268 pages

Publisher: Nuclear Threat Initiative

[Excerpt]

LEARNING FROM THE COVID-19 PANDEMIC

Nearly two years after the World Health Organization (WHO) recognized COVID-19 as a Public Health Emergency of International Concern, some lessons from the pandemic are clear:

- **Countries' ability to measure the number of COVID-19 cases and deaths depend on their having public health capacities such as diagnostic and screening tests**, which were not adequately established in many countries before the pandemic. For example, the WHO has estimated that six of every seven COVID-19 infections in Africa go undetected due to limited testing capacity.^a As a result, official country reports of cases and deaths may not accurately reflect the full impact of COVID-19.
- **The availability of health security capacities in countries does not automatically translate into protection** from illness, death, and economic consequence. Successful outcomes during a pandemic depend on political will and government readiness and flexibility to use available capacities in a way that aligns with evolving evidence-based public health recommendations for disease containment and mitigation. The public must trust advice from health officials and not face hurdles, such as lost income, if protective recommendations are to be followed.
- **National risk environments—measured by disorderly transfers of power, social unrest, international tensions, and distrust in medical and health advice from the government—can have an outsized impact on a country's ability to successfully use its health security capacities to respond to an emerging outbreak.** The success of disease-mitigation efforts is contingent upon public trust in government, healthcare institutions, and public health professionals. In the absence of trust, public cooperation and compliance with recommendations—including physical distancing, mask mandates, and shutdowns—are likely to fail and be more vulnerable to corrosive misinformation. Countries with those risk factors must develop strategies to minimize their influence—such as working to foster trust and prevent the politicization of a crisis—to enable a successful response.
- **Public health and health system capacities must be coupled with policies and programs that enable all people to comply with public health recommendations.** Universal health coverage, paid sick leave, subsidized childcare, income assistance, and food and housing assistance are examples of policies that helped populations comply with protective public health measures of the COVID-19 pandemic. For example, Ghana and Ukraine both provide wraparound services, such as economic or medical support, to infected patients and their contacts to self-isolate or quarantine. New Zealand raised its minimum wage and began providing weekly benefits to support participation of public health measures in society. Portugal extended temporary citizenship to asylum seekers and migrants during the pandemic, thereby dismantling barriers to accessing healthcare among those populations.

See World Health Organization, "Six in Seven COVID-19 Infections Go Undetected in Africa," October 14, 2021. <https://www.afro.who.int/news/six-seven-covid-19-infections-go-undetected-africa>

Media Release

2021 Global Health Security Index Finds All Countries Remain Dangerously Unprepared for Future Epidemic and Pandemic Threats

Report calls on national and global leaders to sustain and expand upon preparedness capacities developed to fight COVID-19

WASHINGTON, DC (December 8, 2021) — Despite important steps taken by countries to respond to the COVID-19 pandemic, all countries—across all income levels—remain dangerously unprepared to meet future epidemic and pandemic threats, according to the new 2021 Global Health Security (GHS) Index.

The report, released today by the Nuclear Threat Initiative (NTI) and the Johns Hopkins Center for Health Security at the Bloomberg School of Public Health, with research by Economist Impact, measured the capacities of 195 countries to prepare for epidemics and pandemics. The data demonstrate that all countries have insufficient sustained health capacities, leaving the world acutely vulnerable to future health emergencies, including those potentially more devastating than COVID-19. The average overall 2021 GHS Index score is 38.9 out of a possible score of 100. No country scored in the top tier of rankings and no country scored above 75.9.

“COVID-19 offers a devastating illustration of how poor pandemic preparedness and response can impact health and security at every level—local, national and global,” said NTI Co-Chair and CEO Ernest J. Moniz. “The stakes are high, and world leaders need to act. Biological risks are growing in frequency, and all countries need more investment in durable capabilities to address these risks.”

The GHS Index is designed to inform leaders of the foundational elements that are necessary to prepare their countries for future outbreaks and where they should prioritize planning and durable funding. It is not a direct predictor of performance in the face of a health emergency; as COVID-19 has demonstrated—contextual social, political, and cultural phenomena also impact how well a country responds to a biological event.

“Leaders now have a choice,” said Dr. Jennifer Nuzzo, senior scholar at the Johns Hopkins Center for Health Security. “They can make dedicated, sustainable investments in the new capacities created during the COVID-19 response to prepare their countries for the long term, or they can fall back into the decades-long cycle of panic-and-neglect that will leave the world at grave risk for inevitable future public health threats.” ...

:::::
:::::

ICMRA high-level meeting on global health emergencies and regulatory approaches

News 06/12/2021

On 1 and 2 December, International Coalition of Medicines Regulatory Authorities (ICMRA), a group of leading medicines regulatory authorities and experts from around the world, held a high-level meeting to discuss regulatory challenges, including those faced during the ongoing COVID-19 pandemic. Participants from the 24 members and 13 associated members and experts from the World Health Organization and the European Commission also discussed the path towards regulatory alignment on the global response to the Omicron variant.

"The pandemic has increased the urgency for us to converge on responses both to existing regulatory challenges and complex new ones," said Emer Cooke, Chair of ICMRA and EMA's Executive Director. "ICMRA has proven its value during the COVID-19 response, both as a platform for sharing information and best practices and as a venue for providing strategic leadership, active information sharing, pragmatic solutions and regulatory convergence."

One of the goals of the meeting was to exchange information on regulatory approaches to the COVID-19 response, draw lessons learned and identify future priorities and opportunities to strengthen regulatory preparedness for future public health emergencies. Meeting participants also reflected on other important issues that are on the agenda of medicines regulators and public health bodies, including the fight against antimicrobial resistance, medicines for use in pregnancy and supply chain integrity.

The meeting was hosted by the Brazilian National Health Surveillance Agency (ANVISA) and co-chaired by Antonio Barra Torres, Director of ANVISA, and Emer Cooke, Chair of ICMRA and EMA's Executive Director. A meeting report summarising the outcomes of the discussions will be published on the ICMRA website in due course.

::::::

ICMRA Statement on Need for Continued Focus on COVID-19 Therapeutics

07 December 2021

ICMRA presents this statement to highlight the significance of the continued need for development of additional therapeutics to treat and prevent COVID-19.

Since the World Health Organization's declaration of the pandemic in March 2020, remarkable advances in health product development have made a significant impact against COVID-19. These advances include the development and marketing of several new testing devices, numerous disinfectants and sanitizers, different types of personal protective equipment, a variety of products to assist patients in hospitals and intensive care units (ICU), some new treatments, and a number of new vaccines. **While several vaccines have been successfully brought to market and are currently being deployed globally, with several others under development, more efforts are needed to increase the availability of and access to effective treatments across the disease spectrum.**

The International Coalition of Medicines Regulatory Authorities (ICMRA) has been convening since the beginning of the pandemic to share information, discuss scientific requirements for the development of drugs and vaccines for COVID-19, and develop aligned regulatory approaches. ICMRA has hosted workshops and issued several statements to assist regulators, industry, healthcare professionals, patients, and other stakeholders through the pandemic, including a statement on the need to conduct well-designed clinical trials for vaccines and treatments, to support regulatory decision-making.

Building on the actions taken to-date, ICMRA, through international collaboration, pledges to continue the efforts towards developing new therapeutics for COVID-19. This is especially important in order to have treatment options for people who are unable to be vaccinated or who have lower immune response to vaccines (e.g., people who are immunocompromised), and to address issues such as break-through infections, the emergence of SARS-CoV-2 variants with some level of vaccine resistance, and waning

immunity. For these reasons, there is an ongoing need for safe, effective and accessible treatments to complement vaccination.

Some advancements have been made with small molecules, including antivirals and glucocorticoids, to treat severe disease and monoclonal antibodies for prophylaxis or to treat mild-to-moderate COVID-19 in non-hospitalized patients. Many of these treatments have become available in several countries. While these treatments are helpful, all may require parenteral (intravenous or subcutaneous) administration and/or specialized healthcare settings to monitor for adverse events. This necessitates additional treatments with ease of administration and accessibility. Recent advancements in oral antivirals for mild-to-moderate infection are encouraging, and may help fulfill the unmet need for easily accessible options. Furthermore, the entire spectrum of COVID-19 illness could benefit from new treatments (including prevention, early mild-to-moderate disease in non-hospitalized patients, severe disease in hospitalized and ICU patients, and for patients with long-COVID symptoms).

ICMRA calls on researchers, industry, healthcare professionals, health research funding agencies, research institutions, and others to focus development efforts on therapeutics addressing the full spectrum of the COVID-19 disease in all populations and in particular, including underrepresented or underserved populations such as pediatric patients and pregnant individuals. SARS-CoV-2 variants of concern should be prominently addressed in these efforts. ICMRA encourages that application for use in low and middle-income countries, also be a focus in the development of antivirals and other treatments that are safe, effective and easy to deploy.

As expressed in [previous statements](#), ICMRA encourages collaboration to ensure the design of robust clinical trials that can deliver actionable results, with prioritisation of therapeutics with a high probability of success. Additionally, ICMRA will continue to support ongoing and sustained international collaboration on pharmacovigilance and post-approval systems to equip regulators with data and information that supports well-informed and timely action.

:::::
::::

FDA News Release

[Coronavirus \(COVID-19\) Update: FDA Authorizes New Long-Acting Monoclonal Antibodies for Pre-exposure Prevention of COVID-19 in Certain Individuals](#)

December 08, 2021

Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for AstraZeneca's Evusheld (tixagevimab co-packaged with cilgavimab and administered together) for the pre-exposure prophylaxis (prevention) of COVID-19 in certain adults and pediatric individuals (12 years of age and older weighing at least 40 kilograms [about 88 pounds]).

The product is only authorized for those individuals who are not currently infected with the SARS-CoV-2 virus and who have not recently been exposed to an individual infected with SARS-CoV-2. The authorization also requires that individuals either have:

:: moderate to severely compromised immune systems due to a medical condition or due to taking immunosuppressive medications or treatments and may not mount an adequate immune response to COVID-19 vaccination (examples of such medical conditions or treatments can be found in the [fact sheet](#) for health care providers) or;

:: a history of severe adverse reactions to a COVID-19 vaccine and/or component(s) of those vaccines, therefore vaccination with an available COVID-19 vaccine, according to the approved or authorized schedule, is not recommended.

"Vaccines have proven to be the best defense available against COVID-19. However, there are certain immune compromised individuals who may not mount an adequate immune response to COVID-19 vaccination, or those who have a history of severe adverse reactions to a COVID-19 vaccine and therefore cannot receive one and need an alternative prevention option," said Patrizia Cavazzoni, M.D., director of the FDA's Center for Drug Evaluation and Research. "Today's action authorizes the use of the combination of two monoclonal antibodies to reduce the risk of developing COVID-19 in these individuals."...

:::::
:::::

Coronavirus [COVID-19] - WHO

Public Health Emergency of International Concern (PHEIC)

<https://www.who.int/emergencies/diseases/novel-coronavirus-2019>

Weekly Epidemiological and Operational updates

Last update: 10 Dec 2021

Confirmed cases :: 267 865 289 [263 563 622 week ago]

Confirmed deaths :: 5 285 888 [5 232 562 week ago]

Vaccine doses administered: 8 158 815 265 [7 864 123 038 week ago]

:::::

Weekly epidemiological update on COVID-19 - 7 December 2021

WHO


Overview

Globally, weekly COVID-19 case incidence plateaued this week (29 November - 5 December 2021), with over 4 million confirmed new cases reported, similar to the number reported in the previous week's figures. However, new weekly deaths increased by 10% as compared to the previous week, with over 52 500 new deaths reported. As of 5 December, nearly 265 million confirmed cases and over 5.2 million deaths have been reported globally.

In this edition a special focus update is provided on SARS-CoV-2 Variants of Concern (VOCs) and Variants of Interest (VOIs)

An update on Variant of Concern Omicron is also provided and includes the current situation in terms of the epidemiology and transmissibility, clinical severity, risk of reinfection and potential impact on diagnostics, vaccines and therapeutics. As our understanding of the Omicron variant is evolving, these updates will continue as further evidence becomes available.

Figure 1. COVID-19 cases reported weekly by WHO Region, and global deaths, as of 5 December 2021**



**See Annex 2: Data, table, and figure notes



WHO Director General Speeches [selected]

<https://www.who.int/director-general/speeches>

Selected

9 December 2021

Speech

WHO Director-General's opening remarks Global Health Landscape Symposium - 9 December 2021

9 December 2021

Speech

WHO Director-General's opening remarks at the 8th meeting of the Access to COVID-19 Tools Accelerator Facilitation Council - 9 December 2021

8 December 2021

Speech

WHO Director-General's opening remarks at the media briefing on COVID-19 - 8 December 2021

:: The Omicron variant has now been reported in 57 countries, and we expect that number to continue growing. Certain features of Omicron, including its global spread and large number of mutations, suggest it could have a major impact on the course of the pandemic. Exactly what that impact will be is still difficult to know.

:: Any complacency now will cost lives. Many of those who don't die could be left battling long COVID, or post-COVID condition, a disease with debilitating, lingering symptoms that we are only beginning to understand.

:: New data are emerging every day, but scientists need time to complete studies and interpret the results. We must be careful about drawing firm conclusions until we have a more complete picture.

Every day, WHO is convening thousands of experts around the world to share and analyse data and drive research forward.

6 December 2021

Speech

WHO Director-General's opening remarks at the Stakeholder Engagement Event: Progress made so far on implementing the partnerships for vaccine manufacturing in Africa

6 December 2021

Speech

WHO Director-General's opening remarks at the USAID Development Ministerial on COVID-19



Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process 11 November 2021

For 24 vaccine candidates, presents Manufacturer, Name of Vaccine, NRA of Record, Platform, EOI Accepted Status, Pre-submission Meeting Held Status, Dossier Accepted for Review, Status of Assessment; Anticipated/Completed Decision Date

[Full scale view available at title link above]

Vaccines							Guidance Document 11 November 2021		
Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process									
	Manufacturer / WHO EUL holder	Name of Vaccine	NRA of Record	Platform	EOI accepted	Pre-submission meeting held	Dossier accepted for review*	Status of assessment**	Decision date***
1.	 BioNTech Manufacturing GmbH	BNT162b2/COMIRNATY Tozinameran (INN)	EMA	Nucleoside modified mRNA	✓	✓	✓	Finalized: Additional sites: - Baxter Oncology GmbH Germany (DP) - Novartis Switzerland - Mibe Dermapharm Germany (DP) - Delpharm, Saint-Remy FRANCE (DP) - Shelf life extension: 9 months at -70 to -90°C - Sanofi-Aventis Deutschland GmbH Germany Diluent suppliers: - Pfizer Perth, Australia/Fresenius Kabi, USA	31/12/2020
								Finalized: - Pharmacia & Upjohn, Kalamazoo (DP)/PGS - McPherson (DP) - Exelead, Inc. Indianapolis USA	30/06/2021 08/07/2021 16/07/2021 17/09/2021 20/09/2021 06/10/2021 18/06/2021
2.	 AstraZeneca, AB	AZD1222 Vaxzevria	EMA	Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2.	✓	✓	✓	Core data finalized	16 April 2021
3.								Finalized: Additional sites: - SK-Catalent - Wuxi (DS) - Chemo Spain - Amgen Ohio US (DP)	16 April 2021 30 April 2021 04 June 2021 23 July 2021
4.		AZD1222 Vaxzevria	MFDS KOREA	Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2.	✓	✓	✓	Finalized	15 Feb 2021
5.		AZD1222 Vaxzevria	Japan MHLW/PMDA		✓	✓	✓	Finalized: Additional sites: Nipro Pharma Corporation Ise, Japan	09 July 2021 11 October
6.	 Serum Institute of India Pvt. Ltd	AZD1222 Vaxzevria	Australia TGA	Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2.	✓	✓	✓	Finalized: Additional site: Siam Bioscience Co., Ltd Thailand	09 July 2021 11 October 2021
7.		Covishield (ChAdOx1_nCoV-19)	DCGI	Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2.	✓	✓	✓	Finalized: DS and DP Manjeri Bk Pune	15 Feb 2021 12 Nov 2021
8.		Ad26.COV2.S	EMA	Recombinant, replication-incompetent adenovirus type 26 (Ad26) vectored vaccine encoding the (SARS-CoV-2) Spike (S) protein	✓	✓	✓	Core data finalized (US +NL sites) Additional sites: - Merck, Durham, UK (DS) - Future submission - Merck, West Point/PA (DP)	12 March 2021 -25 June 2021 - 02 July 2021 - As submitted - 05 November 2021

Vaccines								Guidance Document 11 November 2021
	Manufacturer / WHO EUL holder	Name of Vaccine	Platform	EOI accepted	Pre-submission meeting held	Dossier accepted for review*	Status of assessment**	Decision date***
9.	moderna Moderna Biotech	mRNA-1273	mRNA-based vaccine encapsulated in lipid nanoparticle (LNP) mRNA-based vaccine encapsulated in lipid nanoparticle (LNP)	✓ ✓	✓ ✓	✓ ✓	Finalized ModernaTx, Norwood (DS) - Catalent Indiana, LLC (DP) - Lonz Biologics, Inc. Portsmouth, USA (DS) - Baxter, Bloomington, USA (DP)	30 April 2021 06 August 2021
10.	Sinopharm / BIBP ¹ Beijing Institute of Biological Products Co., Ltd. (BIBP)	SARS-CoV-2 Vaccine (Vero Cell), Inactivated (InCoV)	NMPA	✓	✓	✓	Finalized 2 and 5 dose presentation (new manufacturing site)	07 May 2021 TBC after ongoing inspection
11.	SINOVAC Sinovac Life Sciences Co., Ltd. Sinovac Life Sciences Co., Ltd.	COVID-19 Vaccine (Vero Cell), Inactivated/Coronavac TM	NMPA	Inactivated, produced in Vero cells	✓	✓	Finalized 2 dose presentation	01 June 2021 30 September 2021
12.	THE NATIONAL CENTER FOR BIOTECHNOLOGY Bharat Biotech, India	Sputnik V	Russian NRA	Human Adenovirus Vector-based Covid-19 vaccine	Additional information submitted	Several meetings have been and continue to be held.	"Rolling" submission incomplete.	Process restarted, awaiting completion of rolling submission and CAPAs to last inspection- Anticipated date will be set once all data is submitted and follow-up of inspection observations completed.
13.	BHARAT BIOTECH Bharat Biotech, India	SARS-CoV-2 Vaccine, Inactivated (Vero Cell)/ COVAXIN	DCGI	Whole-Virion Inactivated Vero Cell	✓	✓	✓	Finalized
14.	Sinopharm / WIBP ²	Inactivated SARS-CoV-2 Vaccine (Vero Cell)	NMPA	Inactivated, produced in Vero cells	✓	✓	Rolling data started 23 July 2021	Ongoing
15.	康希诺生物 CanSinoBio	Ad5-nCoV	NMPA	Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)	✓	✓	Rolling data started 09 August 2021	Ongoing; inspection ongoing
16.	NOVAVAK	NVX-CoV2373/Covaxovax	EMA	Recombinant nanoparticle prefusion spike protein formulated with Matrix-M TM adjuvant.	✓	✓	Rolling data started 19 August 2021	Ongoing
17.	SANOFI	CoV2 preS dTM-A503 vaccine	EMA	Recombinant, adjuvanted	✓		Rolling data started 30 July 2021	TBC
18.	SERUM INSTITUTE OF INDIA PVT. LTD. Guru Nanak Devi Trust	NVX-CoV2373/Covaxovax	DCGI	Recombinant nanoparticle prefusion spike protein formulated with Matrix-M TM adjuvant.	✓		Rolling data started 21 September 2021	Ongoing
19.	Clover Biopharmaceuticals	SCB-2019	NMPA	Novel recombinant SARS-CoV-2 Spike (S)-Trimer fusion protein	✓	✓	Rolling data started 20 September	Screened and communicated gaps. Data awaited
20.	Zorecimeran (INN) Contractor and solvent for dispersion for injection; Company code: CVnCoV/CV07090101	Zorecimeran (INN)	EMA	mRNA-based vaccine encapsulated in lipid nanoparticle (LNP)	✓	Application withdrawn by manufacturer		
21.	Zhifei Longcom, China	Recombinant Novel Coronavirus Vaccine (CHO Cell)	NMPA	Recombinant protein subunit	✓	Presubmission planned		

Vaccines								Guidance Document 11 November 2021	
	Manufacturer / WHO EUL holder	Name of Vaccine	NRA of Record	Platform	EOI accepted	Pre-submission meeting held	Dossier accepted for review*	Status of assessment**	Decision date***
22.	Vector State Research Centre of Virology and Biotechnology	EpiVacCorona	Russian NRA	Peptide antigen	Letter received not EOI. Reply sent on 15/01/2021				
23.	IMBCAMS, China	SARS-CoV-2 Vaccine, Inactivated (Vero Cell)	NMPA	Inactivated	Not accepted, still under initial development				
24.	BioCubaFarma - Cuba	Soberana 01, Soberana 02, Soberana Plus Abdala	CECMED	SARS-CoV-2 spike protein conjugated chemically to meningococcal B or tetanus toxoid or Aluminum	Awaiting information on strategy and timelines for submission.				

1. Beijing Institute of Biological Products Co-Ltd
2. Wuhan Institute of Biological Products Co Ltd

* Dossier Submission dates: more than one date is possible because of the rolling submission approach. Dossier is accepted after screening of received submission.

** Status of assessment: 1. Under screening; 2. Under assessment; 3. Waiting responses from the applicant. 4. Risk-benefit decision 5. Final decision made

*** Anticipated decision date: this is only an estimate because it depends on when all the data is submitted under rolling submission and when all the responses to the assessors' questions are submitted.

COVID Vaccine Developer/Manufacturer Announcements

[relevant press releases/announcement from organizations from WHO EUL/PQ listing above]

AstraZeneca

Press Releases

[**Evusheld \(formerly AZD7442\) long-acting antibody combination authorised for emergency use in the US for pre-exposure prophylaxis \(prevention\) of COVID-19**](#)

08 December 2021

Bharat Biotech

Press Releases - No new digest announcements identified

BioCubaFarma – Cuba

[Últimas Noticias - \[Website not responding at inquiry; receiving 403-Forbidden\]](#)

CanSinoBIO

News - [Website not responding at inquiry]

Clover Biopharmaceuticals - China

News - No new digest announcements identified

[Clover Signs COVID-19 Vaccine Supply Agreement with UNICEF](#)

Dec 7,2021

[UNICEF signs supply agreement for Clover COVID-19 vaccine](#)

NEW YORK/COPENHAGEN, 7 December 2021 – UNICEF and Clover Biopharmaceuticals Ltd. have signed a long-term agreement for the supply of the Clover COVID-19 vaccine on behalf of the COVAX Facility.

Through the supply agreement, UNICEF will have access to up to 414 million doses of Clover's COVID-19 vaccine until the end of 2022. These doses were committed to the COVAX Facility through an Advance Purchase Agreement (APA) signed between Gavi, the Vaccine Alliance and Clover Biopharmaceuticals on 30 June 2021. The vaccine will be supplied to participating countries and territories in the COVAX Facility's Advance Market Commitment (AMC), as well as self-financing participants...

Curevac [Bayer Ag – Germany]

News - No new digest announcements identified

Gamaleya National Center

Latest News and Events - No new digest announcements identified [See Russia/RFID below]

IMBCAMS, China

Home - No new digest announcements identified

Janssen/JNJ

Press Releases

Dec 09, 2021 United States

[World Health Organization Strategic Advisory Group of Experts \(SAGE\) Interim Recommendation Supports Use of Johnson & Johnson COVID-19 Vaccine as a Booster](#)

Dec 07, 2021 United States

[Janssen Announces Respiratory Syncytial Virus \(RSV\) Adult Vaccine Candidate Maintains High Efficacy Regardless of Lower Respiratory Tract Disease Severity](#)

Dec 05, 2021 United States

[Johnson & Johnson COVID-19 Booster, Administered Six Months After Two-Dose Regimen of BNT162b2, Shows Substantial Increase in Antibody and T-cell Responses](#)**Moderna**

Press Releases

December 10, 2021

[Moderna Announces Additional 20 Million Doses of COVID-19 Vaccine to COVAX for Supply in 2021 and New Additional Supply Agreement for 2022](#)

December 10, 2021

Moderna Announces Positive Interim Phase 1 Data for mRNA Flu Vaccine and Provides Program Update

Novavax

Press Releases - No new digest announcements identified

Pfizer

Recent Press Releases

12.09.2021

Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 16 Years and Older

12.08.2021

Pfizer and BioNTech Provide Update on Omicron Variant

Sanofi Pasteur

Press Releases - No new digest announcements identified

Serum Institute of India

NEWS & ANNOUNCEMENTS - No new digest announcements identified

Sinopharm/WIBPBIBP

News - No new digest announcements identified

Sinovac

Press Releases - No new digest announcements identified

Vector State Research Centre of Virology and Biotechnology

Home - No new digest announcements identified

Zhifei Longcom, China

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]

[No website identified]

::::::

GSK

Press releases for media

07 December 2021 Medicago and GSK announce positive Phase 3 efficacy and safety results for adjuvanted plant-based COVID-19 vaccine candidate

- :: Primary endpoints and secondary endpoints for which data are available were met in trial dominated by COVID-19 variants
- :: Efficacy demonstrated against all variants seen in the study, including 75.3% efficacy against COVID-19 of any severity caused by the globally dominant Delta variant
- :: Vaccine candidate was well-tolerated, with no related serious adverse events reported in the vaccine group
- :: Final regulatory submission to be filed with Health Canada imminently

07 December 2021 Preclinical studies demonstrate sotrovimab retains activity against the full combination of mutations in the spike protein of the Omicron SARS-CoV-2 variant

Merck

News releases

Merck Announces Pause in Enrollment for Two Phase 3 Clinical Trials of Investigational, Once-Monthly, Oral Islatravir for Pre-Exposure Prophylaxis (PrEP) of HIV-1 infection

December 06, 2021

Novartis

News - No new digest announcements identified

SK Biosciences

Press releases - No new digest announcements identified

Valneva

Press Releases

December 8, 2021

Valneva Signs Advance Purchase Agreement with Bahrain for Inactivated COVID-19 Vaccine VLA2001

.....

.....

UNICEF COVID-19 Vaccine Market Dashboard :: Agreements Table Accessed 11 Dec 2021

An overview of information collected from publicly announced bilateral and multilateral supply agreements [no new agreements since 10/22/2021 reported]



.....

.....

IMF-WHO Vaccine Supply Forecast Dashboard

Updated on 22 November 2021

Many countries are not on track to meet the 40% vaccine coverage target. To make progress towards this target, we must identify: (1) Where and in which countries are the gaps?, and (2) How can gaps be addressed?

The IMF-WHO COVID-19 Vaccine Supply Forecast Dashboard estimates expected month vaccine supply until the end of 2021 by country, product and channel. The tracker builds on the work of the IMF Staff Discussion Note – A Proposal to End the COVID-19 Pandemic (Agarwal and Gopinath, 2021).

3. Gap to 40% and Excess Doses by Country Group

	End-Dec	End-Nov	End-Oct	End-Sep	
	Baseline Scenario	Low Supply Scenario	High Supply Scenario		
Gap to 40% expected coverage					
	World	AMC91	High Income Countries	UMIC (excl. China)	
Number of countries not on track to reach 40% coverage	73	60	0	13	
Number of doses (mn.) needed for all countries to reach 40% coverage	563	539	0	24	
Excess doses above 100% expected coverage					
	World	AMC91	High Income Countries	UMIC (excl. China)	
Number of countries on track to reach above 100% coverage	48	3	39	5	
Number of excess doses (mn.) expected above 100% coverage	637	0	474	77	

:::::::
:::::::

Duke – Launch and Scale Speedometer **The Race for Global COVID-19 Vaccine Equity**

A flurry of nearly 200 COVID-19 vaccine candidates are moving forward through the development and clinical trials processes at unprecedented speed; more than ten candidates are already in Phase 3 large-scale trials and several have received emergency or limited authorization. Our team has aggregated and analyzed publicly available data to track the flow of procurement and manufacturing and better understand global equity challenges. We developed a data framework of relevant variables and conducted desk research of publicly available information to identify COVID vaccine candidates and status, deals and ongoing negotiations for procurement and manufacturing, COVID burden by country, and allocation and distribution plans. We have also conducted interviews with public officials in key countries to better understand the context and challenges facing vaccine allocation and distribution

[accessed 24 July 2021]

[See our COVID Vaccine Purchases research](#)

[See our COVID Vaccine Manufacturing research](#)


[See our COVID Vaccine Donations & Exports research](#)

Overview of donations by top 10 donating countries

Bar chart is ordered by total number of doses pledged.

Donut charts are ordered by proportion of pledged donations shipped.

Country Category:
Top 10 Donating Countries



Data updated on December 1st 2021.

Duke | GLOBAL HEALTH
Innovation Center




Global Dashboard on COVID-19 Vaccine Equity

The Dashboard is a joint initiative of UNDP, WHO and the University of Oxford with cooperation across the UN system, anchored in the SDG 3 Global Action Plan for Healthy Lives and Well-being for All.

Dashboard on Vaccine Equity [accessed 11 Dec 2021]: <https://data.undp.org/vaccine-equity/>
See also visualization on [Vaccine Access](#) and [Vaccine Affordability](#)

High income countries: 1 in 2
people, or



64.94%

have been vaccinated with at least
one dose as of Dec 8, 2021.

[WHO](#)

Low income countries: 1 in 12
people, or



8.35%

have been vaccinated with at least
one dose as of Dec 8, 2021.

[WHO](#)

High income countries have to
increase their health care spending
by

1


0.8%

on average to cover cost of
vaccinating 70% of the population.

[UNDP Survey](#), [WHO](#), [UNICEF](#)

Low income countries have to
increase their health care spending

by



56.6%

on average to cover cost of
vaccinating 70% of the population.

[UNDP Survey](#), [WHO](#), [UNICEF](#)

:::::
:::::

COVID Vaccines – OCHA:: HDX

[COVID-19 Data Explorer: Global Humanitarian Operations](#)

COVID-19 Vaccine Roll-out

11 Dec 2021 | COVAX (WHO,GAVI,CEPI), UNDESA, Press Reports | [DATA](#)

Global COVID-19 Figures: 268M total confirmed cases; 5.3M total confirmed deaths

Global vaccines administered: 8.035B

Number of Countries: 30 [30 week ago]

COVAX Allocations Round 4-9 (Number of Doses): 220M [220M week ago]

COVAX Delivered (Number of Doses): 180M [180M week ago]

Other Delivered (Number of Doses): 300M [300M week ago]

Total Delivered (Number of Doses): 480M [480M week ago]

=====

=====


Multilateral Leaders Task Force on COVID-19 [IMF, World Bank Group, WHO, WTO]

<https://data.covid19taskforce.com/data>

A global effort to help developing countries access and deliver COVID-19 vaccines, testing, and therapeutics, as they work to end the pandemic and boost economic recovery.

The International Monetary Fund, World Bank Group, World Health Organization and World Trade Organization have joined forces to accelerate access to COVID-19 vaccines, therapeutics and diagnostics by leveraging multilateral finance and trade solutions, particularly in low- and middle-income countries.

Website accessed **11 Dec 2021**: <https://data.covid19taskforce.com/data> The global view below is complemented by country-specific dashboards [here](#).



Doses ?

● Required Doses (end 2021)

6.2B doses

(40% of total population)

● Required Doses (mid 2022)

10.9B doses

(70% of total population)

● Secured Vaccines / Expected Vaccine Supply


18.5B doses

● Delivered Doses

9.7B doses

● Doses Administered

8.3B doses



:::::::
:::::::

Our World in Data

Coronavirus (COVID-19) Vaccinations [Accessed 11 Dec 2021]

:: [55.9%](#) of the world population has received at least one dose of a COVID-19 vaccine.


:: [8.41 billion doses](#) have been administered globally, and [34.49 million](#) are now administered each day.

:: Only [7.1%](#) of people in low-income countries have received at least one dose.

Share of the population fully vaccinated against COVID-19, Dec 10, 2021

Our World in Data

Total number of people who received all doses prescribed by the vaccination protocol, divided by the total population of the country.



Source: Official data collated by Our World in Data - Last updated 11 December 2021, 15:10 (London time)

Note: Alternative definitions of a full vaccination, e.g. having been infected with SARS-CoV-2 and having 1 dose of a 2-dose protocol, are ignored to maximize comparability between countries.

OurWorldInData.org/coronavirus • CC BY


► Dec 13, 2020 — ○ Dec 10, 2021

Share of the population fully vaccinated against COVID-19, Dec 10, 2021

Our World in Data

Total number of people who received all doses prescribed by the vaccination protocol, divided by the total population of the country.

+ Add country



Source: Official data collated by Our World in Data - Last updated 11 December 2021, 15:10 (London time)

Note: Alternative definitions of a full vaccination, e.g. having been infected with SARS-CoV-2 and having 1 dose of a 2-dose protocol, are ignored to maximize comparability between countries.

OurWorldInData.org/coronavirus • CC BY

► Dec 13, 2020 — ○ Dec 10, 2021

:::::
:::::

U.S.: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

FDA

Press Announcements

[**December 10, 2021 - Coronavirus \(COVID-19\) Update: December 10, 2021**](#)

[**December 9, 2021 - Coronavirus \(COVID-19\) Update: FDA Expands Eligibility for Pfizer-BioNTech COVID-19 Booster Dose to 16- and 17-Year-Olds**](#)

[**December 8, 2021 - Coronavirus \(COVID-19\) Update: FDA Authorizes New Long-Acting Monoclonal Antibodies for Pre-exposure Prevention of COVID-19 in Certain Individuals**](#)

[**December 7, 2021 - Coronavirus \(COVID-19\) Update: December 7, 2021**](#)

[**December 7, 2021 - FDA In Brief: FDA Takes New Steps Aimed at Advancing Development of Individualized Medicines to Treat Genetic Diseases**](#)

Vaccines and Related Biological Products Advisory Committee- FDA

<https://www.fda.gov/advisory-committees/blood-vaccines-and-other-biologics/vaccines-and-related-biological-products-advisory-committee>

No meetings on [calendar](#)

:::::

White House [U.S.]

Briefing Room – Selected Major COVID Announcements

[**Remarks by President Biden in Meeting with Members of the White House COVID-19 Response Team on the Omicron Variant**](#)

December 09, 2021 • Speeches and Remarks

[**Press Briefing by White House COVID-19 Response Team and Public Health Official**](#)

December 07, 2021 • Press Briefings

U.S. Department of State

<https://www.state.gov/coronavirus/releases/>

Media Notes

Press Statement

[**Administrator Samantha Power at the Development Ministerial on COVID-19**](#)

December 6, 2021

...For the past year, the story of COVID-19 around the world has been a struggle for vaccine equity—rich nations replete with doses while poorer nations fought to secure vaccines for their people. But thanks to the efforts of many many people and many institutions and nations including the United

States, thanks to the tireless work of COVAX, the African Union, and other regional leaders, that story is now changing fast.

Over the past year, the United States has committed 1.2 billion vaccines to partner countries and delivered more than 290 million of those. We have invested in vaccine production capacity in countries like India, South Africa, and Senegal, so that in the future, fewer people would have to depend on vaccine donations from wealthy countries. All of this has been done with no strings attached or expectations—we do it because it is the right thing to do but it is also, we know, the smart thing to do.

Today, and this is the point I really want to stress, **we are at an inflection point. The appeal from our partner nations has expanded. They are not just asking for doses; they are urging us to provide support that will allow them to administer those doses. Vaccines from some bilateral donors are finally arriving, but they are often hitting the tarmac too close to their expiration date for local health systems to distribute them.** In other cases, a lack of cold chain capacity or a shortage of healthcare workers limits a country's ability to get vaccines to those who need them.

And finally, many countries are battling a lack of confidence in vaccinations amidst misinformation and willful disinformation, a phenomenon virtually every country on earth—including the United States—has had to confront and is confronting. As a result, despite the availability of doses, we are seeing a growing number of countries postpone or even turn them down out of concern they may not be able to get them into people's arms.

From this day forward, I hope we can ramp up our focus and our ambition on securing not only vaccines but actual vaccinations.

This is going to require a historic mobilization—but it is one that can build on past efforts. Since COVID-19 first emerged, the United States has worked with many of you and your institutions, or nations, to help prevent the pandemic's spread, to distribute badly needed health supplies, and encourage the uptake of vaccines. In more than 100 countries, the U.S. Government has spent more than \$950 million to help supply countries with everything from the ultra-cold freezers they need to keep vaccines at subzero temperatures to the refrigerated trucks needed to get them where they need to go. We've also trained health workers to give shots and monitor for outbreaks, and designed public information campaigns that help fight rumors and build the confidence needed to overcome vaccine hesitancy...

:::::
:::::

Europe: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

European Medicines Agency

News & Press Releases

[**News: International regulators stress continued need for COVID-19 therapeutics \(new\)**](#)

Last updated: 10/12/2021

[**News: EMA and ECDC recommendations on heterologous vaccination courses against COVID-19 \(new\)**](#)

Last updated: 07/12/2021
[See Perspectives above for detail]

News: ICMRA high-level meeting on global health emergencies and regulatory approaches (new)

Last updated: 06/12/2021

News: EMA recommends approval for use of RoActemra in adults with severe COVID-19 (new)

CHMP, Last updated: 06/12/2021

::::::

European Centre for Disease Prevention and Control

<https://www.ecdc.europa.eu/en>

Latest Updates

Publication & Data

Epidemiological update: Omicron variant of concern (VOC) – data as of 11 December 2021 (12:00)

Epidemiological update

11 Dec 2021

As of 11 December 2021, 732 confirmed cases of SARS-CoV-2 Omicron variant of concern (VOC) cases have been reported in the European Union and European Economic Area (EU/EEA).

Confirmed cases have been reported by 22 countries: Austria (17), Belgium (30), Croatia (3), Czechia (5), Cyprus (3), Denmark (195), Estonia (15), Finland (20), France (59), Germany (77), Greece (3), Iceland (20), Ireland (6), Italy (13), Latvia (5), Liechtenstein (1), the Netherlands (62), Norway (109), Portugal (49), Romania (3), Spain (14), and Sweden (23), according to information from public sources. One new country (Cyprus) has reported SARS-CoV-2 Omicron variant of concern (VOC) cases since yesterday and in addition, a number of probable cases are reported in several countries....

::::::



European Centre for Disease Prevention and Control

COVID-19 Vaccine Tracker

Cumulative uptake of at least one dose in the total population in EU/EEA	Cumulative uptake of full vaccination in the total population in EU/EEA
71.3%	66.9%

Accessed 11 Dec 2021

<https://vaccinetracker.ecdc.europa.eu/public/extensions/COVID-19/vaccine-tracker.html#uptake-tab>

::::::

European Commission


<https://ec.europa.eu/commission/presscorner/home/en>

No new digest content identified.

::::::

::::::

Africa: COVID-19 – Announcements/Regulatory Actions/Deployment



Accessed 11 Dec 2021. Full scale, interactive dashboard available at:
<https://africacdc.org/covid-19-vaccination/>

::::::

::::::

Russia: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Russia: Sputnik V – "the first registered COVID-19 vaccine"

<https://sputnikvaccine.com/newsroom/pressreleases/>

Press Releases

Recommendations of EMA and ongoing combo studies support mix&match approach pioneered by Sputnik team to fight COVID

Press release, 07.12.2021

RDIF ready to provide the one-shot Sputnik Light vaccine and Sputnik M vaccine (for adolescents) as it develops strategic cooperation with partners in India to fight COVID

Press release, 06.12.2021

Moscow, December 6, 2021 – Partnership between Russia and India in the fight against COVID has already demonstrated significant results, and the Russian Direct Investment Fund (RDIF, Russia's sovereign wealth fund) strives to expand it through providing the one-shot Sputnik Light vaccine and Sputnik M vaccine (for adolescents).

... RDIF has also provided India's regulator with documents for registration of Sputnik M – the vaccine for adolescents aged 12-17. Russia's Health Ministry registered Sputnik M on November 24, 2021. It has become a new member of the Sputnik vaccines family and is offered to international markets joining Sputnik V and Sputnik Light.

Subject to positive decision of India's authorities, Sputnik M could become the first foreign registered vaccine for adolescents in the country and make an important contribution in protecting the younger population....

The one-shot Sputnik Light vaccine authorized in Argentina as a standalone vaccine and a booster shot

Press release, 06.12.2021

Saudi Arabia has joined more than 100 countries accepting visitors vaccinated with Sputnik V following extensive work between Ministry of Health of Saudi Arabia and RDIF, supported by the Ministry of Investments of Saudi Arabia

Press release, 05.12.2021

:::::
:::::

India: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Ministry of Health and Family Welfare

<https://www.mohfw.gov.in/>

COVID-19 INDIA as on :
11 December 2021, 08:00
IST (GMT+5:30)

(↑↓ Status change since
yesterday)

Active (0.27%)

93277 (1666↓)

Discharged (98.36%)

34114331 (9265↑)

Deaths (1.37%)

475128 (393↑)

COVID-19 Vaccination
as on : 11 December
2021, 08:00 IST
(GMT+5:30)

Total Vaccination : 1,31,99,92,482 (76,36,569↑)

Government of India – Press Information Bureau

Latest Press Releases

COVID-19 Vaccination Update - Day 330

:: India's cumulative vaccination coverage reaches nearly 133 Crore
:: More than 81 lakh Vaccine doses administered today till 7 pm

Posted On: 11 DEC 2021 8:11PM by PIB Delhi

Indian Council for Medical Research (ICMR)

<https://www.icmr.gov.in/media.html>

Press Releases

No new digest content identified.

:::::

:::::

China: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

National Health Commission of the People's Republic of China [to 11 Dec 2021]

<http://en.nhc.gov.cn/>

News

Dec 11: Daily briefing on novel coronavirus cases in China

On Dec 10, 31 provincial-level regions and the Xinjiang Production and Construction Corps on the Chinese mainland reported 87 new cases of confirmed infections.

Beijing administers over 2m COVID-19 vaccine doses to children

2021-12-10

BEIJING -- As of 4 pm Wednesday, more than 2 million doses of COVID-19 vaccines had been administered in Beijing to the city's children aged between 3 and 11, local authorities said on Dec 9.

Starting from Oct 28, the Chinese capital began offering COVID-19 vaccination to children aged between 3 and 11. Nearly 1.37 million minors of this age group have been vaccinated.

:::::

:::::

:::::

Emergencies

POLIO

Public Health Emergency of International Concern (PHEIC)

<https://polioeradication.org/polio-today/polio-now/this-week/>

Polio this week as of 08 December 2021

:: An updated version of the nOPV2-cVDPV2 fact sheet has been released in [English](#) and [French](#).

Summary of new WPV and cVDPV viruses this week (AFP cases and ES positives):

- **Afghanistan:** one WPV1 case
- **Cameroon:** one cVDPV2 case and one positive environmental sample
- **Nigeria:** 18 cVDPV2 cases and 15 positive environmental samples

:::::

::::::

WHO/OCHA Emergencies

Health emergencies list - WHO

"The health emergencies list details the disease outbreaks, disasters and humanitarian crises where WHO plays an essential role in supporting countries to respond to and recover from emergencies with public health consequences."

[Afghanistan crisis](#) [Last apparent update: 18 Oct 2021]

[Crisis in Northern Ethiopia](#) [Last apparent update: 1 June 2021]

[Ebola outbreak, Democratic Republic of the Congo, 2021](#) [Last apparent update: 17 Aug 2021]

[Ebola outbreak outbreak, N'Zerekore, Guinea, 2021](#) [Last apparent update: 17 Aug 2021]

[Coronavirus disease \(COVID-19\) pandemic](#) [See COVID above]

[Ebola outbreak, Equateur Province, Democratic Republic of the Congo, 2020](#)

[Last apparent update: 17 Aug 2021]

[Ebola outbreak, North Kivu, Ituri, Democratic Republic of the Congo, 2018 – 2020](#)

[Last apparent update: 17 Aug 2021]

[Ebola outbreak, Democratic Republic of the Congo, 2018](#) [Last apparent update: 24 July 2018]

[Yemen crisis](#) [Last apparent update: 12 February 2021]

[Syria crisis](#) [Last apparent update: 18 June 2021]

[Somalia crisis](#) [Last apparent update: 24 March 2018]

[Nigeria crisis](#) [Last apparent update: 1 Oct 2021]

[Ebola outbreak, Democratic Republic of the Congo, 2017](#) [Last apparent update: 17 Aug 2021]

[Zika virus disease outbreak, 2015-2016](#) [Last apparent update: 24 Jan 2020]

[Ebola outbreak: West Africa, 2014-2016](#) [Last apparent update: 17 Aug 2021]

[Iraq crisis](#) [Last apparent update: 9 Jan 2008]

[South Sudan crisis](#) [Last apparent update: 23 Sep 2020]

[Avian influenza A \(H7N9\) virus outbreak](#) [Last apparent update: 13 September 2021]

[Middle East respiratory syndrome \(MERS-CoV\) outbreak](#) [Last apparent update: 8 July 2019]

[**Influenza A \(H1N1\) virus, 2009-2010 pandemic**](#) [Last apparent update: 10 Aug 2010]

::::::

UN OCHA – Current Emergencies

Current Corporate Emergencies

Afghanistan

Afghanistan: ICCT Real-Time Response Overview Situation Report (8 December 2021)

HIGHLIGHTS

:: Humanitarians seek US\$606 million as part of the [Flash Appeal](#) to provide prioritised multi-sectoral assistance to 11 million people in the four remaining months of 2021. As at 7 December, the Flash Appeal is now over 100 per cent funded. While humanitarians remain grateful for the generous contribution by the donor community, all commitments have not been translated to actions on the ground as partners continue to face liquidity challenges amid the financial system crisis. The absence of these challenges would enable humanitarian partners to further scale up the response at a higher pace and reach more people in need of assistance...

Northern Ethiopia

Ethiopia - Northern Ethiopia Humanitarian Update Situation Report, 9 Dec 2021

::::::

::::::

WHO & Regional Offices [to 11 Dec 2021]

<https://www.who.int/>

Selected News, Statements

10 December 2021

News release

Two decades dedicated to capacity building for health emergency preparedness and response

9 December 2021

Highlights

Quality of HIV Care: from guidance to implementation

9 December 2021

News release

WHO and Global Fund warn inequalities block progress towards ending AIDS, TB and malaria

9 December 2021

Departmental news

WHO works to scale-up support to low- and middle-income countries (LMICs) to address antimicrobial resistance (AMR) thanks to support from the Kingdom of Saudi Arabia

9 December 2021

Departmental news

Updated interim recommendations for the use of the Janssen Ad26.COV2.S (COVID-19) vaccine

9 December 2021

Statement

WHO continues to support its conditional recommendation for the dapivirine vaginal ring as an additional prevention option for women at substantial risk of HIV

9 December 2021

Departmental news

Neglected tropical diseases: WHO launches survey to expand its offer of online training courses

8 December 2021

Departmental news

Health in the World of Work

8 December 2021

Departmental news

New partnership to combat antimicrobial resistance in gonorrhoea

8 December 2021

Departmental news

Schistosomiasis and soil-transmitted helminthiases: treating millions of people, despite the pandemic

7 December 2021

Departmental news

"The public health impact of chemicals: knowns and unknowns" is now available in the Persian language

7 December 2021

News release

WHO accelerates work on nutrition targets with new commitments

7 December 2021

Departmental news

The Collective Service: supporting RCCE in emergencies

7 December 2021

News release

WHO recommends against the use of convalescent plasma to treat COVID-19

.....

Weekly Epidemiological Record, Vol. 96, No. 49, pp. 597–612 10 December 2021

- :: Rapid COVID-19 vaccination roll-out among indigenous populations in Brazil
- :: Update on vaccine-derived poliovirus outbreaks— worldwide, January 2020– June 2021

::::::

WHO Regional Offices

Selected Press Releases, Announcements

WHO African Region AFRO

- :: 09 December 2021 [Omicron spreads but severe cases remain low in South Africa](#)
- :: 08 December 2021 [COVID-19 pandemic slows progress against tuberculosis](#)
- :: 07 December 2021 [Africa cuts HIV infections, deaths but key targets still elusive](#)

WHO Region of the Americas PAHO

No new digest content identified

WHO South-East Asia Region SEARO

No new digest content identified

WHO European Region EURO

- :: [Providing urgent health care to migrants in Belarus](#) 10-12-2021
- :: [Contact tracing during a pandemic: Gintare's story from Lithuania](#) 10-12-2021
- :: [Recognizing health and care workers in the WHO European Region](#) 10-12-2021

WHO Eastern Mediterranean Region EMRO

- :: [Omicron VOC questions and answers](#)
- :: [Universal Health Coverage Day, 12 December](#) 9 December 2021
- :: [WHO donates 260 000 packs of intravenous solutions to Islamic Republic of Iran](#) 6 December 2021
- :: [King Salman Humanitarian Aid and Relief Centre provides lifeline for millions across Yemen](#) 5 December 2021

WHO Western Pacific Region

- :: [8 December 2021 Six ways to protect yourself and those around you during the holiday season](#)

::::::

WHO Events

<https://www.who.int/news-room/events/2>

[Selected]

WHO STI Research Priority Setting Technical Advisory Group

14 December 2021 18:00 – 19:00 UTC Time

Global expenditure on health: Public spending on the rise?

15 December 2021 14:00 – 15:30 UTC Time

WHO Global Competency Standards for Refugee and Migrant Health Services – Strengthening the health workforce to provide quality health services to refugees and migrants

16 December 2021 14:00 – 15:00 CET

::::::

New WHO Publications

<https://www.who.int/publications/i>

Selected Titles

9 December 2021

[State of inequality: HIV, tuberculosis and malaria](#)

[See Perspectives above for detail]

9 December 2021

[Annexes to the interim recommendations for use of the Janssen Ad26.COV2.S vaccine](#)

9 December 2021

[Interim recommendations for the use of the Janssen Ad26.COV2.S \(COVID-19\) vaccine](#)

8 December 2021

[WHO Human Health Risk Assessment Toolkit: Chemical Hazards, second edition](#)

8 December 2021

[Addressing violence against women in health and multisectoral policies: a global status report](#)

7 December 2021

[Food systems for health: information brief](#)

7 December 2021

[Therapeutics and COVID-19](#)

Overview

The WHO Therapeutics and COVID-19: living guideline contains the Organization's most up-to-date recommendations for the use of therapeutics in the treatment of COVID-19. The latest version of this living guideline is available in pdf format (via the 'Download' button) and via an online platform, and is updated regularly as new evidence emerges.

This seventh version of the WHO living guideline now contains 11 recommendations, including two new recommendations regarding convalescent plasma. No further updates to the previous existing recommendations were made in this latest version...

7 December 2021

[Interim recommendations for use of the Moderna mRNA-1273 vaccine against COVID-19](#)

6 December 2021

[COVID-19 and the social determinants of health and health equity: evidence brief](#)

6 December 2021

[World malaria report 2021](#)

6 December 2021

[Sexual and reproductive health and rights: Infographic snapshot](#)

6 December 2021

[Towards developing WHO's agenda on well-being](#)

6 December 2021

[Health Promotion Glossary of Terms 2021](#)

6 December 2021

[Enhancing uptake of voluntary medical male circumcision among adolescent boys and men at higher risk...](#)

6 December 2021

[Safeguarding the future: giving priority to the needs of adolescent and young mothers living with HIV](#)

6 December 2021

[Workshop on external competence assessment and national competence assessment for malaria microscopists...](#)

6 December 2021

[Sixth Meeting of the WHO South-East Asia Regional Verification Commission for measles and rubella](#)

:::::
:::::
:::::

CDC/ACIP [U.S.] [to 11 Dec 2021]

<http://www.cdc.gov/media/index.html>

<https://www.cdc.gov/vaccines/acip/index.html>

Latest News Releases, Announcements [Selected]

[CDC Expands COVID-19 Booster Recommendations to 16-and-17-year-olds](#) Thursday,

December 9, 2021

“Today, CDC is strengthening its booster recommendations and encouraging everyone 16 and older to receive a booster shot. Although we don’t have all the answers on the Omicron variant, initial data suggests that COVID-19 boosters help broaden and strengthen the protection against Omicron and other variants. We know that COVID-19 vaccines are safe and effective, and I strongly encourage adolescents ages 16 and 17 to get their booster if they are at least 6 months post their initial Pfizer vaccination series.”

[CDC Launches Two Global Networks, Awards \\$22 Million to Combat Antimicrobial Resistance and Infectious Diseases](#) Tuesday, December 7, 2021

[Transcript: New Vital Signs Report The HIV epidemic remains severe among gay and bisexual men - What can be done to end the epidemic for everyone?](#) Tuesday, December 7, 2021

ACIP Meetings

No new meetings listed.

MMWR News Synopsis Friday, December 3, 2021

Selected Content

:: [Symptoms of Depression, Anxiety, Post-Traumatic Stress Disorder, and Suicidal Ideation Among State, Tribal, Local, and Territorial Public Health Workers During the COVID-19 Pandemic — United States, March–April 2021](#)

:: [Vital Signs: HIV Infection, Diagnosis, Treatment, and Prevention Among Gay, Bisexual, and Other Men Who Have Sex with Men — United States, 2010–2019](#)

:: [Correction and Republication: Symptoms of Depression, Anxiety, Post-Traumatic Stress Disorder, and Suicidal Ideation Among State, Tribal, Local, and Territorial Public Health Workers During the COVID-19 Pandemic — United States, March–April 2021](#)

Coronavirus Disease 2019 (COVID-19)- CDC

Approximately 25 announcements/reports/data summaries.

:: [12/11/21 Omicron Variant: What You Need to Know](#)

:: [12/10/21 EARLY RELEASE: Booster and Additional Primary Dose COVID-19 Vaccinations Among Adults Aged ≥65 Years — United States, August 13, 2021–November 19, 2021](#)

:::::

:::::

Africa CDC [to 11 Dec 2021]

<http://www.africacdc.org/>

News

Press Releases

Progress made so far in implementing the Partnerships for African Vaccine Manufacturing (PAVM) – Framework for Action. Kigali, Rwanda, 06-07 December 2021

Kigali, 06 December 2021. The 39th Ordinary Session of the African Union’s Executive Council decision EX.CL/Dec. 1129 (XXXIX) recognized the Partnerships for African Vaccine Manufacturing PAVM as the coordinating mechanism and its leadership of the development of a continental vaccine manufacturing strategy and a framework for action. The Africa Centres for Disease Control and Prevention (Africa CDC) and its partners have led the establishment of the PAVM with a clear mandate, operating model and governance structure. The four core mandates of the PAVM are to:

1. Steward a continental strategy that maintains scale and cost-competitiveness of local manufacturing and promotes equity and security for all
2. Support partnerships to create a conducive business environment that will encourage the emergence of a thriving manufacturing base
3. Play intermediation and partner role between Member States and the global community of supporters on an as-needed basis
4. Communicate updates and serve as the central source of information for Africa vaccine manufacturing

:::::

:::::

China CDC <http://www.chinacdc.cn/en/>

National Health Commission of the People's Republic of China [to 11 Dec 2021]

<http://en.nhc.gov.cn/>

News

[Dec 11: Daily briefing on novel coronavirus cases in China](#)

On Dec 10, 31 provincial-level regions and the Xinjiang Production and Construction Corps on the Chinese mainland reported 87 new cases of confirmed infections.

[Beijing administers over 2m COVID-19 vaccine doses to children](#)

2021-12-10

BEIJING -- As of 4 pm Wednesday, more than 2 million doses of COVID-19 vaccines had been administered in Beijing to the city's children aged between 3 and 11, local authorities said on Dec 9.

Starting from Oct 28, the Chinese capital began offering COVID-19 vaccination to children aged between 3 and 11. Nearly 1.37 million minors of this age group have been vaccinated.

Children between 3 and 11 can only be inoculated under the condition that their guardians have been well-informed and offer their voluntary consent...

National Medical Products Administration – PRC [to 11 Dec 2021]

<http://english.nmpa.gov.cn/>

News

[Over 2.57b COVID-19 vaccine doses administered on Chinese mainland](#)

2021-12-10

Over 2.57 billion COVID-19 vaccine doses had been administered on the Chinese mainland as of Wednesday, data from the National Health Commission showed on Dec 9.

[Antibody combination therapy approved to treat COVID-19](#)

2021-12-10

China approved on Dec 8 the use of a monoclonal neutralizing antibody cocktail for COVID-19 treatment created by Brii Biosciences, making it the first antibody combination therapy against the disease to get the green light in the country.

[CCDC Weekly - Weekly Reports: Current Volume \(3\)](#)

2021-12-10 / No. 50 COVID-19 ISSUE (21)

[View PDF of this issue](#)

- [Perspectives: On Coexistence with COVID-19: Estimations and Perspectives](#)
- [Perspectives: Papua New Guinea Under the COVID-19 Pandemic and Public Health Support from the World Health Organization](#)
- [Outbreak Reports: Exploring the Bridge Cases' Role in the Transmission of the SARS-CoV-2 Delta Variant — Ruili City, Yunnan Province, China, July–September 2021](#)
- [Methods and Applications: Feasibility of Booster Vaccination in High-Risk Populations for Controlling Coronavirus Variants — China, 2021](#)
- [Notes from the Field: Whole-Genome Sequences Analysis Displays Relationship of SARS-CoV-2 Delta Variant Between Four Local Cases and Passengers of a Flight from South Africa — Shenzhen City, Guangdong Province, China, June 2021](#)

:::::
:::::
:::::

Contents [click to move among sections]

- :: [Milestones - Perspectives](#)
- :: [Coronavirus \[COVID-19\] - WHO](#)
- :: [Emergencies](#)
- :: [Organization Announcements](#)
- :: [Journal Watch](#)

:::::
:::::
:::::

Organization Announcements

Editor's Note:

Careful readers will note that the number and range of organizations now monitored in our *Announcements* section below has grown as the impacts of the pandemic have spread across global economies, supply chains and programmatic activity of multilateral agencies and INGOs.

Paul G. Allen Frontiers Group [to 11 Dec 2021]

<https://alleninstitute.org/news-press/>

News

No new digest content identified.

BARDA – U.S. Department of HHS [to 11 Dec 2021]

<https://www.phe.gov/about/barda/Pages/default.aspx>

News

[**December 08, 2021: FDA Authorizes New Long-Acting Monoclonal Antibodies for Pre-exposure Prevention of COVID-19 in Certain Individuals**](#)

[**December 03, 2021: FDA Expands Authorization of Two Monoclonal Antibodies for Treatment and Post-Exposure Prevention of COVID-19 to Younger Pediatric Patients, Including Newborns**](#)

BMGF - Gates Foundation [to 11 Dec 2021]

<https://www.gatesfoundation.org/ideas/media-center>

Press Releases and Statements

No new digest content identified.

Bill & Melinda Gates Medical Research Institute [to 11 Dec 2021]

<https://www.gatesmri.org/>

The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people
No new digest content identified.

CARB-X [to 11 Dec 2021]

<https://carb-x.org/>

News

No new digest content identified.

Center for Vaccine Ethics and Policy – GE2P2 Global Foundation [to 11 Dec 2021]

<https://centerforvaccineethicsandpolicy.net/>

News/Analysis/Statements

:: Past weekly editions and posting of all segments of ***Vaccines and Global Health: The Week in Review*** are [available here](#).

:: [**Informed Consent: A Monthly Review – December 2021**](#) is now posted [here](#)

CEPI – Coalition for Epidemic Preparedness Innovations [to 11 Dec 2021]

<http://cepi.net/>

Latest News

Gritstone bio and CEPI expand vaccine agreement to tackle Omicron variant

06 December, 2021; Emeryville, California and Oslo, Norway—Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, and CEPI, the Coalition for Epidemic Preparedness Innovations, today announced the expansion of their agreement in order to support the development of a self-amplifying mRNA (SAM) vaccine designed to tackle the Omicron COVID-19 variant. CEPI will provide up to \$5 million in additional funding to conduct a Phase 1 clinical trial of Gritstone's Omicron vaccine candidate in South Africa, where a CEPI-funded clinical trial of Gritstone's Beta variant COVID-19 vaccine is due to begin shortly. The SARS-CoV-2 T cell epitopes (TCEs) administered within Gritstone's SAM COVID-19 vaccines are minimally impacted by mutations found within the Omicron variant, reinforcing the platform's potential to address both Omicron and future variants of concern...

DARPA – Defense Advanced Research Projects Agency [to 11 Dec 2021]

<https://www.darpa.mil/news>

News

12/8/2021

DARPA Successfully Transitions Synthetic Biomanufacturing Technologies to Support National Security Objectives

Launched in 2010, DARPA's Living Foundries program aimed to enable adaptable, scalable, and on-demand production of critical, high-value molecules by programming the fundamental metabolic processes of biological systems to generate a vast number of complex molecules. These molecules were often prohibitively expensive, unable to be domestically sourced, and/or impossible to manufacture using traditional synthetic chemistry approaches. As a proof of concept, DARPA intended

to produce 1,000 molecules and material precursors spanning a wide range of defense-relevant applications including industrial chemicals, fuels, coatings, and adhesives.

12/6/2021

Leveraging AI to Accelerate Development of Scientific Models

In August 2018, DARPA released its first AI Exploration (AIE) opportunity called Automating Scientific Knowledge Extraction (ASKE). Unlike DARPA's typical four-year programs, AIEs are designed to be fast-tracked (~18 months in duration) research efforts that help determine the feasibility of an AI concept. The goal of the ASKE project was to develop AI technologies capable of automating some of the manual processes of scientific knowledge discovery, curation, and application. It identified how and where AI could accelerate the process of scientific modeling, and ultimately improve researchers' ability to conduct rigorous and timely experimentation and validation.

Duke Global Health Innovation Center [to 11 Dec 2021]

<https://dukeghic.org/>

Our Blog

No new digest content identified.

EDCTP [to 11 Dec 2021]

<http://www.edctp.org/>

The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials

News

No new digest content identified.

Emory Vaccine Center [to 11 Dec 2021]

<http://www.vaccines.emory.edu/>

Vaccine Center News

No new digest content identified.

European Vaccine Initiative [to 11 Dec 2021]

<http://www.euvaccine.eu/>

Latest News News, Events

No new digest content identified.

Fondation Merieux [to 11 Dec 2021]

<http://www.fondation-merieux.org/>

News, Events

No new digest content identified.

Gavi [to 11 Dec 2021]

<https://www.gavi.org/>

News Releases

10 December 2021

Gavi and Moderna reach agreement for additional supply to COVAX

:: Agreement will make up to an additional 150 million doses of the Moderna COVID-19 vaccine available to COVAX Facility participants in Q2 and Q3 2022, at the lowest tiered price

:: Gavi and Moderna have also agreed to advance availability of 20 million doses – originally scheduled to be available in Q1 2022 – to Q4 2021

GHIT Fund [to 11 Dec 2021]

<https://www.ghitfund.org/newsroom/press>

GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that No new digest content identified.

Global Fund [to 11 Dec 2021]

<https://www.theglobalfund.org/en/news/>

News & Stories

News

WHO and Global Fund Warn Inequalities Block Progress Towards Ending AIDS, TB and Malaria

09 December 2021

[See Perspectives above for detail]

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to 11 Dec 2021]

<https://www.glopid-r.org/news/>

News

No new digest content identified.

Hilleman Laboratories [to 11 Dec 2021]

<http://www.hillemanlabs.org/>

News & Insights

Press Release

Hilleman Laboratories establishes pilot manufacturing facility for vaccine development in Singapore with support from Singapore Economic Development Board

New facility is part of first-of-its-kind vaccine development and manufacturing hub in Singapore

Singapore, 6 December 2021: Hilleman Laboratories, an organisation with a mission to develop affordable vaccines and biologics against infectious diseases, today announced a first-of-its-kind vaccine and biologics development and manufacturing hub in Singapore. Established with the support of the Singapore Economic Development Board (EDB), the hub comprises a 30,000 square foot current Good Manufacturing Practices (cGMP) facility at 138 Depot Road and a state-of-the art research and development (R&D) facility at Biopolis which began operations in April 2021. Hilleman Laboratories is

investing close to SGD 80 million (USD 58 million) in operations, infrastructure and capacity building over the next five years...

HHMI - Howard Hughes Medical Institute [to 11 Dec 2021]

<https://www.hhmi.org/news>

Press Room

No new digest content identified

Human Vaccines Project [to 11 Dec 2021]

<http://www.humanvaccinesproject.org/>

News

HVP COVID Report

Dec 09, 2021

[Wayne Koff: Harnessing the Power of AI to Understand Human Immunity](#)

IAVI [to 11 Dec 2021]

<https://www.iavi.org/newsroom>

Latest News

No new digest content identified.

International Coalition of Medicines Regulatory Authorities [ICMRA]

<http://www.icmra.info/drupal/en/news>

Selected Statements, Press Releases, Research

No new digest content identified.

ICRC [to 11 Dec 2021]

<https://www.icrc.org/en/whats-new>

Selected News Releases, Statements, Reports

[South Sudan: Looting of a health care unit during armed violence in Unity State](#)

People wounded during the clashes have had to walk up to 30km across heavily flooded terrain to access health care following the looting of Padeah Primary Health Unit.

09-12-2021 | Statement

[Dakar Forum on Peace and Security: "There can be no security without human security"](#)

The following comments were made by Peter Maurer, president of the International Committee of the Red Cross, as part of a panel discussion on challenges to stability and emergence in Africa in a post-COVID-19 world, at the Dakar International Forum o

06-12-2021 | Statement

IFFIm

<http://www.iffim.org/>

Press Releases/Announcements

No new digest content identified.

IFRC [to 11 Dec 2021]

<http://media.ifrc.org/ifrc/news/press-releases/>

Selected Press Releases, Announcements

09/12/2021

[**Ethiopia: IFRC steps up emergency response amid “ove...**](#)

06/12/2021

[**IFRC President Francesco Rocca meets with Russian Pr...**](#)

Moscow/Geneva, 6 December 2021 – The President of the International Federation of Red Cross and Red Crescent Societies (IFRC) Francesco Rocca, met in the late afternoon of the 5th of December with the President of the Russian Federation, Vladimir Putin.

During the meeting, President Rocca discussed humanitarian priorities and challenges, such as; the COVID-19 pandemic, the equitable distribution of vaccines, the migration crisis at the border between Belarus and Poland, how to strengthen support to the Russian Red Cross, and the critical role of local actors to respond to emergencies...

06/12/2021

[**Indonesia: Rescue and relief critical after Mount Se...**](#)

Institut Pasteur [to 11 Dec 2021]

<https://www.pasteur.fr/en/press-area>

Press Documents

Press Info

01.12.2021

[**Virus related to SARS-CoV-2 found in bats in Cambodia**](#)

What are the origins of SARS-CoV-2? This is the world's most pressing scientific puzzle. Its pieces scattered throughout the world are currently being sought out by scientists. Their goal: to track down the culprit for the largest health crisis to hit the globe in the past century. Scientists at the Institut Pasteur in Paris and the Institut Pasteur du Cambodge have identified a coronavirus in bats in Cambodia whose genome is 92.6% related to SARS-CoV-2. These findings were published in [Nature Communications](#) on November 9, 2021.

IOM / International Organization for Migration [to 11 Dec 2021]

<http://www.iom.int/press-room/press-releases>

News - Selected

News

10 Dec 2021

[**Rising Migrant Deaths Top 4,400 This Year: IOM Records More Than 45,000 Since 2014**](#)

ISC / International Science Council [to 11 Dec 2021]

<https://council.science/current/>

ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.

News

News Press releases

Researchers combat new threats to key human rights

10.12.2021

Scientists call for global science systems that protect the human right to science in a new paper published today by the International Science Council (ISC).

Report: <https://stories.council.science/science-freedom-responsibility/>

Press releases

Global Commission on Science Missions for Sustainability Launched

09.12.2021

Political leaders, scientists, and influential personalities issue emergency warning on sustainability inaction, establish a Global Commission to mobilize a \$100 million a year global fund for Sustainability Science Missions

Commission members include former NZ PM Helen Clark, former UNESCO Director General Irina Bokova, film producer James Cameron and philanthropist Julie Wrigley

9 December 2021 Paris, France: The International Science Council (ISC) is a non-governmental organization with a unique global membership bringing together over 200 international scientific unions and associations, as well as national and regional scientific organizations, academies, and research councils. Today in Paris, its new President, Peter Gluckman, former Chief Science Adviser to the government of New Zealand, announced the 'Global Commission on Science Missions for Sustainability' with the sole purpose of pressing the reset button to accelerate the progress towards the Sustainable Development Goals (SDGs).

IVAC [to 11 Dec 2021]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

Updates; Events

No new digest content identified.

IVI [to 11 Dec 2021]

<http://www.ivi.int/>

IVI News & Announcements

IVI, ADB SEADS, IPK, ICARS, and the Danish Embassy in Korea launch webinar on combatting antimicrobial resistance

December 7, 2021 — The International Vaccine Institute (IVI), Asian Development Bank Southeast Asia Development Solutions (ADB SEADS), Institut Pasteur Korea (IPK), the International Centre for Antimicrobial Resistance Solutions (ICARS), and the Embassy of Denmark in Korea held a joint webinar today to bring awareness to antimicrobial resistance (AMR) and discuss sustainable solutions to the global public health threat...

Johns Hopkins Center for Health Security [to 11 Dec 2021]

<https://www.centerforhealthsecurity.org/news/center-news/>

Center News

2021 Global Health Security Index Finds All Countries Remain Dangerously Unprepared for Future Epidemic and Pandemic Threats

December 8, 2021

[See Perspectives above for detail]

MSF/Médecins Sans Frontières [to 11 Dec 2021]

<http://www.msf.org/>

Latest [Selected Announcements]

DRC Ebola outbreaks

DRC's thiteenth Ebola outbreak

Crisis Update 9 Dec 2021

Following a series of community deaths in North Kivu province, Democratic Republic of Congo (DRC), the DRC Ministry of Health declared an outbreak of Ebola on 8 October. The outbreak is concentrated in Beni health zone. This is the thirteenth epidemic in DRC, the third in North Kivu province and the second in Beni health zone.

Coronavirus COVID-19 pandemic

Responding to COVID-19: Global Accountability Report 5 - May to September 2021

Report 8 Dec 2021

Kenya

Urgent solutions needed for refugees as camps set to close

Press Release 6 Dec 2021

Kenya

In search of dignity: Refugees in Kenya face a reckoning

Report 6 Dec 2021

National Academy of Medicine - USA [to 11 Dec 2021]

<https://nam.edu/programs/>

Selected News/Programs/Events

No new digest content identified.

National Academy of Sciences - USA [to 11 Dec 2021]

<http://www.nasonline.org/news-and-multimedia/>

News

No new digest content identified.

National Vaccine Program Office - U.S. HHS [to 11 Dec 2021]

<https://www.hhs.gov/vaccines/about/index.html>

Upcoming Meetings/Latest Updates

No new digest content identified.

NIH [to 11 Dec 2021]

<http://www.nih.gov/news-events/news-releases>

News Releases

[Experimental mRNA HIV vaccine safe, shows promise in animals](#)

December 9, 2021 — NIH scientists developed vaccine platform.

An experimental HIV vaccine based on mRNA—the same platform technology used in two highly effective COVID-19 vaccines—shows promise in mice and non-human primates, according to scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. Their results, published in *Nature Medicine*, show that the novel vaccine was safe and prompted desired antibody and cellular immune responses against an HIV-like virus...

OECD [to 11 Dec 2021]

<http://www.oecd.org/newsroom/publicationsdocuments/bydate/>

Newsroom

[Portugal: use post-COVID-19 recovery plan to bolster growth and public finances, says OECD](#)

Portugal's economy is recovering from the COVID-19 crisis, thanks to swift and effective policy action and a successful vaccine rollout. As the recovery progresses, it is important to pursue investment and structural reforms that will raise living standards, strengthen public finances and put growth on a strong, sustainable and resilient path, according to a new OECD report.

10-December-2021

[Pensions protected during COVID-19 pandemic but ageing challenges persist, says OECD](#)

The COVID-19 pandemic has taken a heavy toll among elderly people although retirees have seen their pension payments well protected across OECD countries. Future pension entitlements have also been well protected thanks to the exceptional policy response to the crisis, according to a new OECD report.

8-December-2021

PATH [to 11 Dec 2021]

<https://www.path.org/media-center/>

Press Releases

No new digest content identified.

Sabin Vaccine Institute [to 11 Dec 2021]

<http://www.sabin.org/updates/pressreleases>

Statements and Press Releases

No new digest content identified.

UNAIDS [to 11 Dec 2021]

<http://www.unaids.org/en>

Selected Press Releases/Reports/Statements

10 December 2021

Co-creating a new global initiative to end AIDS among children, adolescents and their mothers

10 December 2021

The need for wider implementation of people-centred differentiated service delivery for HIV testing and treatment in Africa

9 December 2021

High-level continental seminar on the right to health and social protection in Africa

9 December 2021

Social protection systems addressing inequalities

8 December 2021

Empowering sex workers through social enterprises

8 December 2021

We need your thoughts and ideas on how to end AIDS among children, adolescents and mothers—new global online survey launched

8 December 2021

Leaders from Eastern and Southern Africa recommit to the education, health and well-being of adolescents and young people

7 December 2021

The importance of comprehensive sexuality education for Africa's young people

6 December 2021

Commemorating World AIDS Day in the Central African Republic

UNHCR Office of the United Nations High Commissioner for Refugees [to 11 Dec 2021]
<http://www.unhcr.org/en-us/media-centre.html>

Selected News Releases, Announcements

No new digest content identified.

UNICEF [to 11 Dec 2021]

<https://www.unicef.org/media/press-releases>

Press Releases, News Notes, Statements [Selected]

Press release

12/10/2021

UNICEF welcomes announcement of next Executive Director

NEW YORK, 10 December 2021 – UNICEF welcomes United Nations Secretary-General António Guterres' announcement today that Catherine M. Russell will succeed Henrietta H. Fore as UNICEF Executive Director.

Ms. Russell brings to the role decades of experience in developing innovative policy that empowers underserved communities around the world; delivering high-impact programmes that protect women

and girls, including in humanitarian crises; building, elevating, and managing diverse workforces; and mobilizing resources and political support for a broad range of initiatives.

She currently serves as Assistant to the President and Director of the White House Office of Presidential Personnel. From 2013 to 2017, she served as Ambassador-at-Large for Global Women's Issues at the U.S. Department of State. In that post, she integrated women's issues across all elements of U.S. foreign policy, represented the United States in more than 45 countries, and worked with foreign governments, multilateral organizations, and civil society. She was the principal architect of the ground-breaking "U.S. Global Strategy to Empower Adolescent Girls"...

Press release

12/08/2021

[COVID-19 'biggest global crisis for children in our 75-year history' – UNICEF](#)

On its 75th anniversary, UNICEF warns that COVID-19 is rolling back virtually every measure of progress for children, including a staggering 100 million more children plunged into poverty

Press release

12/08/2021

[More than US\\$27 billion committed to tackle global malnutrition and hunger crisis at the Tokyo Nutrition for Growth Summit](#)

45 low- and middle-income countries led with strong policy and financial commitments

Press release

12/07/2021

[UNICEF launches US\\$9.4 billion emergency funding appeal for children affected by conflict, the climate crisis and COVID-19](#)

Funds will support essential programs for over 177 million children in need across 145 countries and territories through 2022

News note

12/07/2021

[UNICEF signs supply agreement for Clover COVID-19 vaccine](#)

NEW YORK/COPENHAGEN, 7 December 2021 – UNICEF and Clover Biopharmaceuticals Ltd. have signed a long-term agreement for the supply of the Clover COVID-19 vaccine on behalf of the COVAX Facility.

Through the supply agreement, UNICEF will have access to up to 414 million doses of Clover's COVID-19 vaccine until the end of 2022. These doses were committed to the COVAX Facility through an Advance Purchase Agreement (APA) signed between Gavi, the Vaccine Alliance and Clover Biopharmaceuticals on 30 June 2021. The vaccine will be supplied to participating countries and territories in the COVAX Facility's Advance Market Commitment (AMC), as well as self-financing participants.

This agreement further expands UNICEF's COVID-19 vaccine supplier base. UNICEF has already signed supply agreements with vaccine manufacturers including the Serum Institute of India, Pfizer, AstraZeneca, Human Vaccine, Moderna, Janssen Pharmaceutica NV, Sinopharm and Sinovac. The addition of Clover's vaccine to the portfolio provides further diversification by providing access to the first protein subunit vaccine.

Procurement by UNICEF under this agreement is conditional on the product achieving an Emergency Use Listing (EUL) from WHO, to confirm the quality, safety and efficacy of the vaccine...

Statement

12/06/2021

UNICEF and WHO, in partnership with Gavi, ask Ted Chaiban to serve as Global Lead Coordinator for COVID Vaccine Country Readiness and Delivery

NEW YORK, 6 December 2021 – “I am pleased to announce that UNICEF and WHO, in partnership with Gavi, have asked Ted Chaiban, currently UNICEF Regional Director Middle East and North Africa, to serve as Global Lead Coordinator for COVID Vaccine Country Readiness and Delivery.

“This decision is an expression of our joint commitment to reinvigorate efforts to turn vaccines into vaccinations in low- and middle-income countries.

“With vastly improved supply, the world no longer has a global vaccine supply problem; it has a vaccine equity and delivery problem. More than 80 per cent of the world’s vaccines have gone to G20 countries while millions of people, including healthcare workers, in low-income countries are still unprotected.

“As vaccine doses become increasingly available in the coming weeks, it is critical that countries are prepared, resourced and able to roll them out.

“With support from COVAX, the African Union, AVAT and other partners, governments in low-income countries have made important progress in getting ready to receive and administer COVID-19 vaccines at a scale sufficient to meet global objectives. However, they still face significant challenges in scaling up capacity....

Press release

12/06/2021

Learning losses from COVID-19 could cost this generation of students close to \$17 trillion in lifetime earnings

World Bank-UNESCO-UNICEF report lays out the magnitude of the education crisis

Unitaid [to 11 Dec 2021]

<https://unitaid.org/>

Featured News

09 December 2021

Landscape report launched on novel technologies for the prevention of HIV, STIs, and unwanted pregnancy

Geneva – Emerging technologies that can prevent HIV, other sexually transmitted infections and unwanted pregnancies through a single administration method have the potential to respond better to user preferences, simplify service delivery, alleviate stigma, and reduce health risks. Currently, over two dozen of these tools, called multipurpose prevention technologies, are in development, demonstrating the opportunity to accelerate health impact and help achieve global health targets, according to a new landscape report jointly launched today by Unitaid, the Children’s Investment Fund Foundation, and the Initiative for Multipurpose Prevention Technologies...

Vaccine Equity Cooperative [nee Initiative] [to 11 Dec 2021]

<https://vaccineequitycooperative.org/news/>

News

No new digest content identified.

Vaccination Acceptance & Demand Initiative [Sabin] [to 11 Dec 2021]

<https://www.vaccineacceptance.org/>

Announcements

Focusing on Marginalized Communities

Get to Know Five of Our 2021 Social and Behavioral Research Grant Partners

December 9, 2021

By: Abigail Quinn, BA, Deeva Agrawat, MSc, Kate Hopkins, PhD, MPH

The Sabin Vaccine Institute's Vaccine Acceptance & Demand initiative is proud to provide funding to 10 grant partners awarded through the 2021 Social and Behavioral Research Grants Program. This blog is the second in a series examining the selected research projects based on one of three themes: vaccine equity, marginalized communities and social media/messaging...

Vaccine Confidence Project [to 11 Dec 2021]

<http://www.vaccineconfidence.org/>

News, Research and Reports

No new digest content identified.

Vaccine Education Center – Children's Hospital of Philadelphia [to 11 Dec 2021]

<http://www.chop.edu/centers-programs/vaccine-education-center>

News

No new digest content identified.

Wellcome Trust [to 11 Dec 2021]

<https://wellcome.ac.uk/news>

News. Opinion, Reports

News

People worldwide want their governments to value science

During a global pandemic, it's vital that governments endorse and implement scientific recommendations. We asked people around the world whether they felt their government valued scientific advice throughout the coronavirus pandemic.

8 December 2021

The Wistar Institute [to 11 Dec 2021]

<https://www.wistar.org/news/press-releases>

Press Releases

No new digest content identified.

WFPHA: World Federation of Public Health Associations [to 11 Dec 2021]

<https://www.wfpha.org/>

Latest News - Blog

Human Rights Day 2021

Dec 10, 2021

...The International Federation of Social Workers and World Federation of Public Health Association jointly advance a statement to continue to advocate with the United Nations, governments, companies and civil societies for the promotion of equity and respect for human rights, starting with the equitable distribution of vaccines and guaranteeing the universal right to sustainable development...

Statement link: <https://drive.infomaniak.com/app/share/141741/8c4e56c4-6620-4c77-8095-e967707d8c8a/preview/pdf/39843>

World Bank [to 11 Dec 2021]

<http://www.worldbank.org/en/news/all>

Selected News, Announcements

[Ukraine to Expand COVID-19 Vaccination, with Additional World Bank Financing](#)

WASHINGTON, December 10, 2021 – The World Bank's Board of Executive Directors approved today \$150 million in Additional Financing for the Ukraine Emergency COVID-19 Response and Vaccination Project...

Date: December 10, 2021 Type: Press Release

[Learning Losses from COVID-19 Could Cost this Generation of Students Close to \\$17 Trillion in Lifetime Earnings](#)

World Bank-UNESCO-UNICEF report lays out the magnitude of the education crisis WASHINGTON, DC, Dec. 6, 2021—This generation of students now risks losing \$17 trillion in lifetime earnings in present...

Date: December 06, 2021 Type: Press Release

[The State of the Global Education Crisis: A Path to Recovery](#)

The global disruption to education caused by the COVID-19 pandemic is without parallel and the effects on learning are severe. The crisis brought education systems across the world to a halt, with school...

Date: December 03, 2021 Type: Publication

World Organisation for Animal Health (OIE) [to 11 Dec 2021]

<https://www.oie.int/en/media/news/>

Press Releases, Statements

[OIE Statement on monitoring white-tailed deer for SARS-CoV-2](#)

Statements

3 December 2021

Recent scientific research has shown a high prevalence of SARS-CoV-2 infection within white-tailed deer populations in North America. This is the first time that the virus has been detected at population levels in wildlife. This discovery requires further research to determine if white-tailed deer could become a reservoir of SARS-CoV-2 and to assess other animal or public health implications. As they do not show clinical signs of infection, white-tailed deer should be monitored for the possibility of becoming a silent reservoir.

While there is currently no evidence of transmission of SARS-CoV-2 from white tailed-deer to humans, there appears to have been multiple introductions of the virus into white-tailed deer populations by humans. We encourage countries to raise awareness with both hunters, and those living or working with wildlife, to avoid unnecessary interactions with wildlife and to avoid leaving any human waste or objects in forested areas that may be ingested or touched by deer and other wildlife...

WTO - World Trade Organisation [to 11 Dec 2021]

http://www.wto.org/english/news_e/news_e.htm

WTO News and Events

Monitoring report shows continued but slow rollback of COVID-19 related trade restrictions

9 December 2021

WTO members showed restraint in the imposition of new trade-restrictive measures related to COVID-19 and continued to roll back restrictions adopted earlier in the pandemic, according to the Director-General's annual overview report on trade-related developments. Despite a slowdown in new trade restrictions unrelated to the pandemic, the stockpile of unpealed restrictive measures that has accumulated since the monitoring exercise started in 2009 now affects traded merchandise worth an estimated USD 1.5 trillion, or nearly 9% of world imports.

::::::

ARM [Alliance for Regenerative Medicine] [to 11 Dec 2021]

<https://alliancerm.org/press-releases/>

Selected Press Releases

No new digest content identified.

BIO [to 11 Dec 2021]

<https://www.bio.org/press-releases>

Press Releases, Letters, Testimony, Comments [Selected]

No new digest content identified.

DCVMN – Developing Country Vaccine Manufacturers Network [to 11 Dec 2021]

<http://www.dcvmn.org/>

News; Upcoming events



Dr. Suresh Jadhav (1949-2021)

Pune, 07 December 2021 – Today was a sad day for all in the vaccine industry with the passing away of Dr. Suresh Jadhav: a humble, friendly yet very knowledgeable and highly respected person. His warm smile and kind words are still on our minds.

We convey our heartiest and sincere condolences to his family and close friends on his loss and pay tribute to his exemplary lifetime and dedication to vaccines and immunization.

He was a great vaccinologist and one of the persons with a pivotal role, for over 40 years, in building the Serum Institute of India global outreach, in getting WHO pre-qualification of several products.

Dr. Jadhav was also instrumental in leading the Developing Countries Vaccine Manufacturers Network (DCVMN) into its current status and we owe him a huge debt of gratitude.

We shall continue our work in respect of his life, legacy and memory.

DCVMN members

ICBA – International Council of Biotechnology Associations [to 11 Dec 2021]

<https://internationalbiotech.org/news/>

News

No new digest content identified.

IFPMA [to 11 Dec 2021]

<http://www.ifpma.org/resources/news-releases/>

Selected Press Releases, Statements, Publications

[Industry Position Paper: Optimising Post-Approval Change Management to Facilitate Continuous Supply of Medicines and Vaccines](#)

10 December 2021

Industry Position

:: Industry acknowledges its commitment to continue improving its strategic and predictive planning and proactive communication of changes to help facilitate global supply.

:: In addition, Industry believes that global regulatory convergence of post-approval changes to Marketing Authorisations (MAs) using science and risk-based approaches will enable a more efficient management of quality and supply improvements and will facilitate patients' access to innovative medicines and vaccines.

:: National Regulatory Authorities (NRAs) should: establish national or regional guidelines in line with international standards (with regard to a risk based classification of changes and standardization of requirements) [1, 2]; have clear procedural guidance including timelines; and implement reliance pathways to accelerate the approval of changes

[1] - *WHO Annex 3—Guidelines on procedures and data requirements for changes to approved biotherapeutic products WHO Technical Report Series N° 1011, 2018*

[2] - *WHO Annex 4: Guidelines on procedures and data requirements for changes to approved vaccines WHO Technical Report Series N° 993, 2015*

International Generic and Biosimilar Medicines Association [IGBA]

<https://www.igbamedicines.org/>

News

No new digest content identified.

International Alliance of Patients' Organizations – IAPO [to 11 Dec 2021]

<https://www.iapo.org.uk/news/topic/6>

Press and media [Selected]

No new digest content identified.

PhRMA [to 11 Dec 2021]

<http://www.phrma.org/>

Latest News [Selected]

No new digest content identified.

* * * *

Contents [click to move among sections]

- :: [Milestones - Perspectives](#)
- :: [Coronavirus \[COVID-19\] - WHO](#)
- :: [Emergencies](#)
- :: [Organization Announcements](#)
- :: [Journal Watch](#)

* * * *

Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics

Volume 12, 2020 Issue 4

<https://www.tandfonline.com/toc/uabr21/current>

[Reviewed earlier]

AMA Journal of Ethics

Volume 23, Number 12: E905-1005 Dec 2021

<https://journalofethics.ama-assn.org/issue/health-care-and-homelessness>

Health Justice and Diversity in Medical School Admissions

The Association of American Medical Colleges defines members of populations underrepresented in medicine "relative to their numbers in the general population." Diversity motivates key clinical and professional educational goals that can be sources of common ground when conflict emerges about which kinds of diversity should matter most and how applicants' memberships in minoritized groups should be regarded in admissions processes. Diversification and inclusion strategies vary in how effectively they motivate equity or retention among members of different groups in medicine, so how influential they should be is hotly contested and worthy of ethical investigation.

[No digest content identified]

American Journal of Infection Control

December 2021 Volume 49 Issue 12 p1457-1578

<http://www.ajicjournal.org/current>

[Reviewed earlier]

American Journal of Preventive Medicine

December 2021 Volume 61 Issue 6 p771-928

<https://www.ajpmonline.org/current>

[Reviewed earlier]

American Journal of Public Health

December 2021 111(12)

<http://ajph.aphapublications.org/toc/ajph/current>

EDITORIALS

Reaffirming the Foundations of Public Health in a Time of Pandemic

Writing/Reviewing/Publishing, Other Statistics/Evaluation/Research, Statistics/Evaluation/Research, Epidemiology

Sandro Galea and Roger Vaughan

PERSPECTIVES

Political Races, Religious Congregations, and Inefficacious Measures Amid the Second Wave of COVID-19 in India

Government, Health Service Delivery, Public Health Practice, Global Health

Akshay P. Raut and Nguyen Tien Huy

NOTES FROM THE FIELD

Using Statewide Electronic Health Record and Influenza Vaccination Data to Plan and Prioritize COVID-19 Vaccine Outreach and Communications in Wisconsin Communities

Mortality, Prevention, Immunization/Vaccines, Statistics/Evaluation/Research, Health Promotion, Community Health

Jessica Bonham-Werling, Allie J. DeLonay, Kristina Stephenson, Korina A. Hendricks, Lauren Bednarz, Jennifer M. Weiss, Matthew Gigot and Maureen A. Smith

American Journal of Tropical Medicine and Hygiene

Volume 105 (2021): Issue 6 (Dec 2021)

<https://www.ajtmh.org/view/journals/tpmd/105/6/tpmd.105.issue-6.xml>

[Reviewed earlier]

Annals of Internal Medicine

November 2021 Volume 174, Issue 11

<http://annals.org/aim/issue>

[Reviewed earlier]

Artificial Intelligence – An International Journal

Volume 301 December 2021

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/301/suppl/C>

[Reviewed earlier]

BMC Cost Effectiveness and Resource Allocation

<http://resource-allocation.biomedcentral.com/>

(Accessed 11 Dec 2021)

[No new digest content identified]

BMJ Global Health

December 2021 - Volume 6 - 12

<https://gh.bmjjournals.org/content/6/12>

[Reviewed earlier]

BMC Health Services Research

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 11 Dec 2021)

[No new digest content identified]

BMC Infectious Diseases

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 11 Dec 2021)

[A re-assessment of 4CMenB vaccine effectiveness against serogroup B invasive meningococcal disease in England based on an incidence model](#)

The four-component serogroup B meningococcal 4CMenB vaccine (Bexsero, GSK) has been routinely given to all infants in the United Kingdom at 2, 4 and 12 months of age since September 2015. After 3 years, Public He...

Authors: Lorenzo Argante, Victoria Abbing-Karahagopian, Kumaran Vadivelu, Rino Rappuoli and Duccio Medini

Citation: BMC Infectious Diseases 2021 21:1244

Content type: Research article

Published on: 11 December 2021

[Number of doses of Measles-Mumps-Rubella vaccine applied in Brazil before and during the COVID-19 pandemic](#)

Due to the social isolation measures adopted in an attempt to mitigate the risk of transmission of SARS-CoV-2, there has been a reduction in vaccination coverage of children and adolescents in several countries...

Authors: Tércia Moreira Ribeiro da Silva, Ana Carolina Micheletti Gomide Nogueira de Sá, Ed Wilson Rodrigues Vieira, Elton Junio Sady Prates, Mark Anthony Beinner and Fernanda Penido Matozinhos

Citation: BMC Infectious Diseases 2021 21:1237

Content type: Research

Published on: 9 December 2021

[COVID-19 vaccine hesitancy in people with migratory backgrounds: a cross-sectional study among Turkish- and German-speaking citizens in Munich](#)

This study aimed to investigate the knowledge, attitudes, behaviors, and COVID-19 vaccine hesitancy of people with migratory backgrounds among Turkish- and German-speaking patients in Munich.

Authors: Zekeriya Aktürk, Klaus Linde, Alexander Hapfelmeier, Raphael Kunisch and Antonius Schneider

Citation: BMC Infectious Diseases 2021 21:1214

Content type: Research

Published on: 6 December 2021

BMC Medical Ethics

<http://www.biomedcentral.com/bmcmedethics/content>

(Accessed 11 Dec 2021)

[No new digest content identified]

BMC Medicine

<http://www.biomedcentral.com/bmcmed/content>

(Accessed 11 Dec 2021)

[No new digest content identified]

BMC Pregnancy and Childbirth

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 11 Dec 2021)

[No new digest content identified]

BMC Public Health

<http://bmcpublichealth.biomedcentral.com/articles>

(Accessed 11 Dec 2021)

[No new digest content identified]

BMC Research Notes

<http://www.biomedcentral.com/bmcresnotes/content>

(Accessed 11 Dec 2021)

[No new digest content identified]

BMJ Evidence-Based Medicine

December 2021 - Volume 26 - 6

<https://ebm.bmjjournals.org/content/26/6>

[Reviewed earlier]

BMJ Open

December 2021 - Volume 11 - 12

<https://bmjopen.bmjjournals.org/content/11/12>

[Reviewed earlier]

Bulletin of the World Health Organization

Volume 99(12); 2021 Dec 1

<https://www.ncbi.nlm.nih.gov/pmc/issues/394921/>

[Reviewed earlier]

Cell

Dec 09, 2021 Volume 184 Issue 25 p6007-6212

<https://www.cell.com/cell/current>

Featured Article

[Infodemics: A new challenge for public health](#)

Sylvie C. Briand, et al.

The COVID-19 information epidemic, or “infodemic,” demonstrates how unlimited access to information may confuse and influence behaviors during a health emergency. However, the study of infodemics is relatively new, and little is known about their relationship with epidemics management. Here, we discuss unresolved issues and propose research directions to enhance preparedness for future health crises.

Child Care, Health and Development

Volume 47, Issue 6 Pages: 733-885 November 2021

<https://onlinelibrary.wiley.com/toc/13652214/current>

[Reviewed earlier]

Clinical Pharmacology & Therapeutics

Volume 110, Issue 6 Pages: 1403-1633 December 2021

<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>

[Reviewed earlier]

Clinical Therapeutics

October 2021 Volume 43 Issue 10 p1627-1808

<http://www.clinicaltherapeutics.com/current>

[Reviewed earlier]

Clinical Trials

Volume 18 Issue 6, December 2021

<https://journals.sagepub.com/toc/ctja/18/6>

[Reviewed earlier]

Conflict and Health

<http://www.conflictandhealth.com/>

[Accessed 11 Dec 2021]

[No new digest content identified]

Contemporary Clinical Trials

Volume 111 December 2021

<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/111/suppl/C>

Research article Full text access

[Assessing the impact of the COVID-19 pandemic on pragmatic clinical trial participants](#)

Brian C. Coleman, Natalie Purcell, Mary Geda, Stephen L. Luther, ... Robert R. Edwards

Article 106619

Research article Full text access

[Public attitudes to the use of remote data collection in clinical research](#)

S. Neumann, A. Bamford, F.E. Lithander, E. Tenison, E.J. Henderson

Article 106595

The CRISPR Journal

Volume 4, Issue 5 / October 2021

<https://www.liebertpub.com/toc/crispr/4/5>

[Reviewed earlier]

Current Genetic Medicine Reports

Volume 9, issue 4, December 2021

<https://link.springer.com/journal/40142/volumes-and-issues/9-4>

[Reviewed earlier]

Current Opinion in Infectious Diseases

December 2021 - Volume 34 - Issue 6

<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>

[Reviewed earlier]

Current Protocols in Human Genetics

Volume 108, Issue 1 December 2020

<https://currentprotocols.onlinelibrary.wiley.com/toc/19348258/current>

[Reviewed earlier]

Developing World Bioethics

Volume 21, Issue 4 Pages: 149-238 December 2021

<https://onlinelibrary.wiley.com/toc/14718847/current>

[Reviewed earlier]

Development in Practice

Volume 31, Issue 8, 2021
<http://www.tandfonline.com/toc/cdip20/current>
[Reviewed earlier]

Disaster Medicine and Public Health Preparedness

Volume 15 - Issue 4 - August 2021
<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>
[Reviewed earlier]

Disasters

Volume 45, Issue 4 Pages: 739-995 October 2021
<https://onlinelibrary.wiley.com/toc/14677717/current>
[Reviewed earlier]

EMBO Reports

Volume 22 Issue 12 6 December 2021
<https://www.embopress.org/toc/14693178/current>
Science & Society 4 November 2021 Open Access

[Toward best practices in research: Role of academic core facilities](#)

Leonardo Restivo et al.

Academic Core Facilities are optimally situated to improve the quality of preclinical research by implementing quality control measures and offering these to their users.

Emerging Infectious Diseases

Volume 27, Number 12—December 2021
<http://wwwnc.cdc.gov/eid/>

Expedited Articles

[Comparative Effectiveness of Coronavirus Vaccine in Preventing Breakthrough Infections among Vaccinated Persons Infected with Delta and Alpha Variants](#)

I. Kislaya et al.

Synopses

[Evaluation of Early Warning, Alert and Response System for Ebola Virus Disease, Democratic Republic of the Congo, 2018–2020 \[PDF - 1.99 MB - 11 pages\]](#)

M. Keita et al.

Epidemics

Volume 37 December 2021
<https://www.sciencedirect.com/journal/epidemics/vol/37/suppl/C>

Research article Open access

[Quantification of the spread of SARS-CoV-2 variant B.1.1.7 in Switzerland](#)

Chaoran Chen, Sarah Ann Nadeau, Ivan Topolsky, Marc Manceau, ... Tanja Stadler

Article 100480

Research article Open access

[Assessing the risk of cascading COVID-19 outbreaks from prison-to-prison transfers](#)

Todd L. Parsons, Lee Worden

Article 100532

Research article Open access

[Challenges of evaluating and modelling vaccination in emerging infectious diseases](#)

Zachary J. Madewell, Natalie E. Dean, Jesse A. Berlin, Paul M. Coplan, ... M. Elizabeth Halloran

Article 100506

Research article Open access

[Sustaining effective COVID-19 control in Malaysia through large-scale vaccination](#)

Pavithra Jayasundara, Kalaiarasu M. Peariasamy, Kian Boon Law, Ku Nurhasni Ku Abd Rahim, ... James M. Trauer

Article 100517

Research article Open access

[Challenges in modelling the dynamics of infectious diseases at the wildlife–human interface](#)

Mick Roberts, Andrew Dobson, Olivier Restif, Konstans Wells

Article 100523

Epidemiology and Infection

Volume 149 - 2021

<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>

[Reviewed earlier]

Ethics & Human Research

Volume 43, Issue 6 Pages: 1-48 November–December 2021

<https://onlinelibrary.wiley.com/toc/25782363/current>

[Reviewed earlier]

Ethics & International Affairs

Fall 2021 (35.3) | October 2021

<https://www.ethicsandinternationalaffairs.org/2021/fall-2021-35-3/>

The editors of Ethics & International Affairs are pleased to present the Fall 2021 issue of the journal! The highlight of this issue is a book symposium organized by Peter Balint on Ned Dobos's Ethics, Security, and the War Machine, featuring contributions by Peter Balint; Neta C. Crawford; C. A. J. Coady; Ned Dobos; Cécile Fabre; Christopher J. Finlay; David Rodin; and Cheyney Ryan. Additionally, the issue includes a feature article by Philipp Gisbertz-Astolfi on the reduced legal equality of combatants in war and an essay by Hendrik Schopmans and Jelena Cupać on ethical AI, gender equality, and illiberal backlash politics. It also contains a review essay by Andreas Papamichail on the global politics of health security, and a book review by Claire Finkelstein.

[Reviewed earlier]

Ethics, Medicine and Public Health

Volume 19 December 2021

<https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/19/suppl/C>

[Reviewed earlier]

The European Journal of Public Health

Volume 31, Issue Supplement_4, November 2021 *Supplement*

<https://academic.oup.com/eurpub/issue/31/5>

COVID-19: What have we learned? What are the public health challenges?

Guest Editors: Dineke Zeegers Paget, Iveta Nagyova, Peter Allebeck

[Reviewed earlier]

Expert Review of Vaccines

Vol 20 (10) 2021

<https://www.tandfonline.com/toc/ierv20/current>

[Reviewed earlier]

Forum for Development Studies

Volume 48, 2021 - Issue 3

<http://www.tandfonline.com/toc/sfds20/current>

[Reviewed earlier]

Genome Medicine

<https://genomemedicine.biomedcentral.com/articles>

[Accessed 11 Dec 2021]

[No new digest content identified]

Global Health Action

Volume 14, Issue 1 (2021)

<https://www.tandfonline.com/toc/zgha20/current?nav=tocList>

[Reviewed earlier]

Global Health: Science and Practice (GHSP)

Vol. 9, No. 3 September 30, 2021

<http://www.ghspjournal.org/content/current>

[Reviewed earlier]

Global Legal Monitor – Library of Congress/USA

<https://www.loc.gov/collections/global-legal-monitor/>

[Accessed 11 Dec 2021]

Article

[Jordan: Criminal Court Sentences Doctors and Medical Technician to Jail for Causing Death of 10 COVID Patients](#)

On December 5, 2021, the first instance criminal court in Jordan's capital, Amman, sentenced five health officials to three years in prison for causing the deaths of 10 COVID-19 patients in a hospital on March 13, 2021, following an oxygen outage. The patients, who were being treated at the New Salt Public Hospital, a large ... Continue reading "Jordan: Criminal Court Sentences Doctors and..."

Contributor: Sadek, George

Date: 2021-12-08

Global Public Health

Volume 16, Issue 12 (2021)

<http://www.tandfonline.com/toc/rgph20/current>

[Reviewed earlier]

Globalization and Health

<http://www.globalizationandhealth.com/>

[Accessed 11 Dec 2021]

[No new digest content identified]

Health and Human Rights

Volume 23, Issue 1, June 2021

<https://www.hhrjournal.org/volume-23-issue-1-june-2021/>

[Reviewed earlier]

Health Economics, Policy and Law

Volume 16 - Issue 4 - October 2021

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>

[Reviewed earlier]

Health Policy and Planning

Volume 36, Issue 10, December 2021

<https://academic.oup.com/heapol/issue/36/10>

[Reviewed earlier]

Health Research Policy and Systems

<http://www.health-policy-systems.com/content>

[Accessed 11 Dec 2021]

[Measuring health science research and development in Africa: mapping the available data](#)

In recent years there have been calls to strengthen health sciences research capacity in African countries. This capacity can contribute to improvements in health, social welfare and poverty reduction through ...

Authors: Clare Wenham, Olivier Wouters, Catherine Jones, Pamela A. Juma, Rhona M. Mijumbi-Deve, Joëlle L. Sobngwi-Tambekou and Justin Parkhurst

Citation: Health Research Policy and Systems 2021 19:142

Content type: Research

Published on: 11 December 2021

Human Gene Therapy

Volume 32, Issue 21-22 / November 2021

<https://www.liebertpub.com/toc/hum/32/21-22>

[New issue; No digest content identified]

Humanitarian Exchange Magazine

Number 79, May 2021

<https://odihpn.org/magazine/localisation-and-local-humanitarian-action/>

Localisation and local humanitarian action

by HPN October 2020

The theme of this edition of *Humanitarian Exchange* is localisation+ and local humanitarian action. Five years ago this week, donors, United Nations (UN) agencies, non-governmental organisations (NGOs), the International Committee of the Red Cross (ICRC) and International Federation of Red Cross and Red Crescent Societies (IFRC) committed within the Grand Bargain to increase multi-year investments in the institutional capacities of local and national responders, and to provide at least 25% of humanitarian funding to them as directly as possible. Since then, there is increasing consensus at policy and normative level, underscored by the Covid-19 pandemic, that local leadership should be supported. Localisation has gone from a fringe conversation among policy-makers and aid agencies in 2016 to a formal priority under the Grand Bargain. Wider global movements on anti-racism and decolonisation have also brought new momentum to critical reflections on where power, knowledge and capacity reside in the humanitarian system. Yet progress has been slow and major gaps remain between the rhetoric around humanitarian partnerships, funding and coordination and practices on the ground.

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)

Volume 17, Issue 10, 2021

<https://www.tandfonline.com/toc/khvi20/current>

[Reviewed earlier]

Immunity

Nov 09, 2021 Volume 54 Issue 11 p2437-2670

<https://www.cell.com/immunity/current>

[Reviewed earlier]

Infectious Agents and Cancer
<http://www.infectagentscancer.com/>
[Accessed 11 Dec 2021]
[No new digest content identified]

Infectious Diseases of Poverty
<http://www.idpjurnal.com/content>
[Accessed 11 Dec 2021]
[No new digest content identified]

International Health
Volume 13, Issue 6, November 2021
<https://academic.oup.com/inthealth/issue/13/6>
[Reviewed earlier]

International Human Rights Law Review
Volume 10 (2021): Issue 1 (Jun 2021)
<https://brill.com/view/journals/hrlr/10/1/hrlr.10.issue-1.xml>
[Reviewed earlier]

International Journal of Community Medicine and Public Health
Vol 8, No 10 (2021) October 2021
<https://www.ijcmph.com/index.php/ijcmph/issue/view/81>
[Reviewed earlier]

International Journal of Epidemiology
Volume 50, Issue 5, October 2021
<https://academic.oup.com/ije/issue>
[Reviewed earlier]

International Journal of Human Rights in Healthcare
Volume 14 Issue 5 2021
<https://www.emerald.com/insight/publication/issn/2056-4902/vol/14/iss/5>
Table of Contents
[Reviewed earlier]

International Journal of Infectious Diseases
December 2021 Volume 113 p1-366
<https://www.ijidonline.com/current>
[Reviewed earlier]

JAMA

December 7, 2021, Vol 326, No. 21, Pages 2105-2223

<https://jamanetwork.com/journals/jama/currentissue>

Original Investigation

Effect of High-Flow Oxygen Therapy vs Conventional Oxygen Therapy on Invasive Mechanical Ventilation and Clinical Recovery in Patients With Severe COVID-19A Randomized Clinical Trial

Gustavo A. Ospina-Tascón, MD, PhD; Luis Eduardo Calderón-Tapia, MD; Alberto F. García, MD, MSc; et al.

JAMA. 2021;326(21):2161-2171. doi:10.1001/jama.2021.20714

This randomized trial assesses the effect of high-flow oxygen therapy through a nasal cannula vs conventional oxygen therapy on 28-day intubation rates and time to clinical recovery among patients with respiratory distress due to COVID-19.

Research Letter

Racial and Ethnic Representation in US Clinical Trials of New Drugs and Biologics, 2015-2019

Milena Lolic, MD, MS; Richardae Araojo, PharmD, MS; Melvyn Okeke, MPH; et al.

JAMA. 2021;326(21):2201-2203. doi:10.1001/jama.2021.16680

This study reviews the participation of racial and ethnic populations at US sites in 2015-2019 to understand the extent to which US trial participation represents the diversity of the US population.

Antibody Titers Before and After a Third Dose of the SARS-CoV-2 BNT162b2 Vaccine in Adults Aged ≥60 Years

Noa Eliakim-Raz, MD; Yaara Leibovici-Weisman, MD; Amos Stemmer, MD; et al.

free access has active quiz

JAMA. 2021;326(21):2203-2204. doi:10.1001/jama.2021.19885

This study assesses antispike (anti-S) IgG antibody titers before and after a third BNT162b2 dose (booster) in individuals aged 60 years and older in Israel.

Viewpoint

Strengthening the FDA's Enforcement of ClinicalTrials.gov Reporting Requirements

Reshma Ramachandran, MD, MPP; Christopher J. Morten, JD, PhD; Joseph S. Ross, MD, MHS
free access

JAMA. 2021;326(21):2131-2132. doi:10.1001/jama.2021.19773

This Viewpoint discusses ways in which the FDA could harness its enforcement tools to bring important missing clinical trial results information to light and demonstrate its commitment to protecting patients through clinical trial transparency.

JAMA Network

COVID-19 Update December 11, 2021

These articles on COVID-19 were published across the JAMA Network in the last week.

JAMA Pediatrics

December 2021, Vol 175, No. 12, Pages 1199-1300

<https://jamanetwork.com/journals/jamapediatrics/currentissue>

Viewpoint

[The Silent Crisis of Pediatric Clinical Practice Guidelines](#)

Corinna J. Rea, MD, MPH; Francisco J. Alvarez, MD; Joel S. Tieder, MD, MPH
JAMA Pediatr. 2021;175(12):1201-1202. doi:10.1001/jamapediatrics.2021.2435

This Viewpoint discusses how to improve the current state of Clinical Practice Guidelines.

JBI Evidence Synthesis

November 2021 - Volume 19 - Issue 11

<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

[Reviewed earlier]

Journal of Adolescent Health

December 2021 Volume 69 Issue 6 p861-1054

<https://www.jahonline.org/current>

[Reviewed earlier]

Journal of Artificial Intelligence Research

Vol. 72 (2021)

<https://www.jair.org/index.php/jair>

[Reviewed earlier]

Journal of Community Health

Volume 46, issue 6, December 2021

<https://link.springer.com/journal/10900/volumes-and-issues/46-6>

[Reviewed earlier]

Journal of Development Economics

Volume 153 November 2021

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/153/suppl/C>

[Reviewed earlier]

Journal of Empirical Research on Human Research Ethics

Volume 16 Issue 5, December 2021

<http://journals.sagepub.com/toc/jre/current>

[Reviewed earlier]

Journal of Epidemiology & Community Health

November 2021 - Volume 75 - 11

<https://jech.bmjjournals.org/content/75/11>

[Reviewed earlier]

Journal of Evidence-Based Medicine

Volume 14, Issue 3 Pages: 171-256 September 2021

<https://onlinelibrary.wiley.com/toc/17565391/current>

[Reviewed earlier]

Journal of Global Ethics

Volume 17, Issue 2, 2021

<http://www.tandfonline.com/toc/rjge20/current>

[New issue; No digest content identified]

Journal of Health Care for the Poor and Underserved (JHCPU)

Volume 32, Number 4, November 2021

<https://muse.jhu.edu/issue/46802>

Table of Contents

[Reviewed earlier]

Journal of Immigrant and Minority Health

Volume 23, issue 6, December 2021

<https://link.springer.com/journal/10903/volumes-and-issues/23-6>

[Reviewed earlier]

Journal of Immigrant & Refugee Studies

Volume 19, 2021_ Issue 4

<https://www.tandfonline.com/toc/wimm20/current>

[Reviewed earlier]

Journal of Infectious Diseases

Volume 224, Issue 6, 15 September 2021

<https://academic.oup.com/jid/issue/224/6>

[Reviewed earlier]

Journal of Medical Ethics

December 2021 - Volume 47 - 12

<http://jme.bmj.com/content/current>

[Reviewed earlier]

Journal of Patient-Centered Research and Reviews

Volume 8, Issue 4 (2021)

<https://digitalrepository.aurorahealthcare.org/jpcrr/>

Cancer Screening

[Reviewed earlier]

Journal of Pediatrics

December 2021 Volume 239 p1-252

<http://www.jpeds.com/current>

[New issue; No digest content identified]

Journal of Pharmaceutical Policy and Practice

<https://joppp.biomedcentral.com/>

[Accessed 11 Dec 2021]

[No new digest content identified]

Journal of Public Health Management & Practice

November/December 2021 - Volume 27 - Issue 6

<https://journals.lww.com/jphmp/pages/currenttoc.aspx>

[Reviewed earlier]

Journal of Public Health Policy

Volume 42, issue 4, December 2021

<https://link.springer.com/journal/41271/volumes-and-issues/42-4>

Editorial

[Public health inequalities, structural missingness, and digital revolution: time to question assumptions](#)

Elena N. Naumova

Content type

Published: 22 November 2021

Pages: 531 - 535

[Stakeholders' assessment of US Centers for Disease Control and Prevention's contributions to the development of National Public Health Institutes in seven countries](#)

Authors (first, second and last of 13) Mahlet A. Woldetsadik, Kaitlin Fitzpatrick, Shelly Bratton

Content type: Original Article

Published: 22 November 2021

Pages: 589 - 601

[Advancing health equity with artificial intelligence](#)

Authors - Nicole M. Thomasian, Carsten Eickhoff

Eli Y. Adashi

Content type: Viewpoint

Published: 22 November 2021

Pages: 602 - 611

Abstract

Population and public health are in the midst of an artificial intelligence revolution capable of radically altering existing models of care delivery and practice. Just as AI seeks to mirror human cognition through its data-driven analytics, it can also reflect the biases present in our collective conscience. In this Viewpoint, we use past and counterfactual examples to illustrate the sequelae of unmitigated bias in healthcare artificial intelligence. Past examples indicate that if the benefits of emerging AI technologies are to be realized, consensus around the regulation of algorithmic bias at the policy level is needed to ensure their ethical integration into the health system. This paper puts forth regulatory strategies for uprooting bias in healthcare AI that can inform ongoing efforts to establish a framework for federal oversight. We highlight three overarching oversight principles in bias mitigation that maps to each phase of the algorithm life cycle.

Journal of Refugee & Global Health

Volume 4, Issue 1 (2021)

<https://ir.library.louisville.edu/rgh/>

[Reviewed earlier]

Journal of the Royal Society – Interface

December 2021 Volume 18 Issue 185

<https://royalsocietypublishing.org/toc/rsif/current>

[Reviewed earlier]

Journal of Travel Medicine

Volume 28, Issue 7, October 2021

<https://academic.oup.com/jtm/issue>

[Reviewed earlier]

Journal of Virology

Volume 95 Number 24 November 2021

<http://jvi.asm.org/content/current>

[Reviewed earlier]

The Lancet

Dec 11, 2021 Volume 398 Number 10317 p2125-2206, e18

<https://www.thelancet.com/journals/lancet/issue/current>

Comment

[Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic](#)

Salim S Abdool Karim, Quarraisha Abdool Karim

[Inactivated SARS-CoV-2 vaccine \(BBV152\)-induced protection against symptomatic COVID-19](#)

Jing-Xin Li, Feng-Cai Zhu

Articles

Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial

Raches Ella, et al. on behalf of the COVAXIN Study Group

We report the clinical efficacy against COVID-19 infection of BBV152, a whole virion inactivated SARS-CoV-2 vaccine formulated with a toll-like receptor 7/8 agonist molecule adsorbed to alum (Algel-IMDG) in Indian adults.

Health Policy

Promoting COVID-19 vaccine acceptance: recommendations from the Lancet Commission on Vaccine Refusal, Acceptance, and Demand in the USA

Saad B Omer, et al.

Summary

Since the first case of COVID-19 was identified in the USA in January, 2020, over 46 million people in the country have tested positive for SARS-CoV-2 infection. Several COVID-19 vaccines have received emergency use authorisations from the US Food and Drug Administration, with the Pfizer–BioNTech vaccine receiving full approval on Aug 23, 2021. When paired with masking, physical distancing, and ventilation, COVID-19 vaccines are the best intervention to sustainably control the pandemic. However, surveys have consistently found that a sizeable minority of US residents do not plan to get a COVID-19 vaccine. The most severe consequence of an inadequate uptake of COVID-19 vaccines has been sustained community transmission (including of the delta [B.1.617.2] variant, a surge of which began in July, 2021). Exacerbating the direct impact of the virus, a low uptake of COVID-19 vaccines will prolong the social and economic repercussions of the pandemic on families and communities, especially low-income and minority ethnic groups, into 2022, or even longer. The scale and challenges of the COVID-19 vaccination campaign are unprecedented. Therefore, through a series of recommendations, we present a coordinated, evidence-based education, communication, and behavioural intervention strategy that is likely to improve the success of COVID-19 vaccine programmes across the USA.

The Lancet Child & Adolescent Health

Dec 2021 Volume 5 Number 12 p837-904, e44-e46

<https://www.thelancet.com/journals/lanchi/issue/current>

[Reviewed earlier]

Lancet Digital Health

Dec 2021 Volume 3 Number 12 e751-e829

<https://www.thelancet.com/journals/landig/issue/current>

[Reviewed earlier]

Lancet Global Health

Dec 2021 Volume 9 Number 12 e1623-e1769

<https://www.thelancet.com/journals/langlo/issue/current>

[Reviewed earlier]

Lancet Infectious Diseases

Dec 2021 Volume 21 Number 12 p1613-1758, e363-e406

<https://www.thelancet.com/journals/laninf/issue/current>
[Reviewed earlier]

Lancet Public Health

Dec 2021 Volume 6 Number 12 e866-e969

<https://www.thelancet.com/journals/lanpub/issue/current>
[Reviewed earlier]

Lancet Respiratory Medicine

Dec 2021 Volume 9 Number 12 p1343-1478, e110-e122

<https://www.thelancet.com/journals/lanres/issue/current>
[Reviewed earlier]

Maternal and Child Health Journal

Volume 25, issue 12, December 2021

<https://link.springer.com/journal/10995/volumes-and-issues/25-12>
[Reviewed earlier]

Medical Decision Making (MDM)

Volume 42 Issue 1, January 2022

<http://mdm.sagepub.com/content/current>
[Reviewed earlier]

The Milbank Quarterly

A Multidisciplinary Journal of Population Health and Health Policy

Volume 99, Issue 3 Pages: 601-852 September 2021

<https://onlinelibrary.wiley.com/toc/14680009/current>
[Reviewed earlier]

Nature

Volume 600 Issue 7888, 9 December 2021

<https://www.nature.com/nature/volumes/600/issues/7888>

Editorial | 08 December 2021

[The UN must get on with appointing its new science board](#)

The decision to appoint a board of advisors is welcome — and urgent, given the twin challenges of COVID and climate change.

Editorial | 07 December 2021

[Omicron: the global response is making it worse](#)

The pandemic will not end while vaccine equity keeps getting pushed to the margins.

Nature Biotechnology

Volume 39 Issue 11, November 2021

<https://www.nature.com/nbt/volumes/39/issues/11>

[Reviewed earlier]

Nature Communications

<https://www.nature.com/subjects/health-sciences/ncomms>

(Accessed 11 Dec 2021)

[No new digest content identified]

Nature Genetics

Volume 53 Issue 12, December 2021

<https://www.nature.com/ng/volumes/53/issues/12>

[New issue; No digest content identified]

Nature Human Behaviour

Volume 5 Issue 11, November 2021

<https://www.nature.com/nathumbehav/volumes/5/issues/11>

[Reviewed earlier]

Nature Medicine

Volume 27 Issue 11, November 2021

<https://www.nature.com/nm/volumes/27/issues/11>

Diversity, Equity and Inclusion in medical research

In this issue, Nature Medicine is launching a Series on Diversity, Equity and Inclusion in medical research. The first installment brings a perspective on the role of funders in addressing the continued lack of diversity in science and medicine in the United States, and an overview of how governmental, societal and philanthropic stakeholders are approaching lack of diversity and inequalities in their research programs.

[Reviewed earlier]

Nature Reviews Genetics

Volume 22 Issue 12, December 2021

<https://www.nature.com/nrg/volumes/22/issues/12>

[Reviewed earlier]

Nature Reviews Immunology

Volume 21 Issue 12, December 2021

<https://www.nature.com/nri/volumes/21/issues/12>

[Reviewed earlier]

Nature Reviews Drug Discovery

Volume 20 Issue 12, December 2021

<https://www.nature.com/nrd/volumes/20/issues/12>

[Reviewed earlier]

New England Journal of Medicine

December 9, 2021 Vol. 385 No. 24

<http://www.nejm.org/toc/nejm/medical-journal>

Perspective

[Covid-19 and the Safety Net — Moving from Straining to Sustaining](#)

J. Knudsen and D.A. Chokshi 2209-2211

[Inequitable Access to Hospital Care — Protecting Disadvantaged Populations during Public Health Emergencies](#)

D.B. White, L. Villarroel, and J.L. Hick

Original Articles

[Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents](#)

K. Ali and Others

[Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar](#)

H. Chemaitelly and Otherse

[Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months](#)

E.G. Levin and Otherse

[Waning Immunity after the BNT162b2 Vaccine in Israel](#)

Y. Goldberg and Others

Pediatrics

Volume 148, Issue 6 December 2021

<https://pediatrics.aappublications.org/>

[Reviewed earlier]

PharmacoEconomics

Volume 39, issue 12, December 2021

<https://link.springer.com/journal/40273/volumes-and-issues/39-12>

[New issue; No digest content identified]

PLoS Biology

<https://journals.plos.org/plosbiology/>

(Accessed 11 Dec 2021)

[No new digest content identified]

PLoS Genetics

<https://journals.plos.org/plosgenetics/>

(Accessed 11 Dec 2021)

[No new digest content identified]

PLoS Medicine

<http://www.plosmedicine.org/>

(Accessed 11 Dec 2021)

Perspective

[SARS-CoV-2 vaccine boosters: The time to act is now](#)

Maya Petersen, Joshua Schwab, Diane V. Havlir

| published 09 Dec 2021 PLOS Medicine

<https://doi.org/10.1371/journal.pmed.1003882>

PLoS Neglected Tropical Diseases

<http://www.plosntds.org/>

(Accessed 11 Dec 2021)

Research Article

[Factors associated with the unwillingness of Jordanians, Palestinians and Syrians to be vaccinated against COVID-19](#)

Sima Zein, Sarah B. Abdallah, Ahmed Al-Smadi, Omar Gammoh, Wajdy J. Al-Awaida, Hanan J. Al-Zein

| published 09 Dec 2021 PLOS Neglected Tropical Diseases

<https://doi.org/10.1371/journal.pntd.0009957>

PLoS One

<http://www.plosone.org/>

[Accessed 11 Dec 2021]

Research Article

[Recurrent SARS-CoV-2 infections and their potential risk to public health – a systematic review](#)

Seth Kofi Abrokwa, Sophie Alice Müller, Alba Méndez-Brito, Johanna Hanefeld, Charbel El Bcheraoui

Research Article | published 09 Dec 2021 PLOS ONE

<https://doi.org/10.1371/journal.pone.0261221>

[Age-related mortality in 61,993 confirmed COVID-19 cases over three epidemic waves in Aragon, Spain. Implications for vaccination programmes](#)

Diego Casas-Deza, Vanesa Bernal-Monterde, Angel Nicolás Aranda-Alonso, Enrique Montil-Miguel, Ana Belén Julián-Gomara, Laura Letona-Giménez, Jose M. Arbones-Mainar

Research Article | published 09 Dec 2021 PLOS ONE

<https://doi.org/10.1371/journal.pone.0261061>

[COVID-19 vaccine hesitancy among the adult population in Bangladesh: A nationwide cross-sectional survey](#)

Mohammad Bellal Hossain, Md. Zakiul Alam, Md. Syful Islam, Shafayat Sultan, Md. Mahir Faysal, Sharmin Rima, Md. Anwer Hossain, Abdullah Al Mamun

Research Article | published 09 Dec 2021 PLOS ONE
<https://doi.org/10.1371/journal.pone.0260821>

Social capital dimensions are differentially associated with COVID-19 vaccinations, masks, and physical distancing

Ibtihal Ferwana, Lav R. Varshney

Research Article | published 09 Dec 2021 PLOS ONE
<https://doi.org/10.1371/journal.pone.0260818>

Good news reduces trust in government and its efficacy: The case of the Pfizer/BioNTech vaccine announcement

Shaun P. Hargreaves Heap, Christel Koop, Konstantinos Matakos, Asli Unan, Nina Weber

Research Article | published 09 Dec 2021 PLOS ONE
<https://doi.org/10.1371/journal.pone.0260216>

Pertussis immunisation in infancy and atopic outcomes: A protocol for a population-based cohort study using linked administrative data

Gladymar Pérez Chacón, Parveen Fathima, Mark Jones, Rosanne Barnes, Peter C. Richmond, Heather F. Gidding, Hannah C. Moore, Thomas L. Snelling

Registered Report Protocol | published 07 Dec 2021 PLOS ONE
<https://doi.org/10.1371/journal.pone.0260388>

Full immunization coverage and associated factors among children aged 12–23 months in Somali Region, Eastern Ethiopia

Zemenu Shiferaw Yadita, Liyew Mekonen Ayehubizu
Research Article | published 07 Dec 2021 PLOS ONE
<https://doi.org/10.1371/journal.pone.0260258>

PLoS Pathogens

<http://journals.plos.org/plospathogens/>

[Accessed 11 Dec 2021]

Current state of Ebola virus vaccines: A snapshot

Courtney Woolsey, Thomas W. Geisbert
Pearls | published 09 Dec 2021 PLOS Pathogens
<https://doi.org/10.1371/journal.ppat.1010078>

PNAS - Proceedings of the National Academy of Sciences of the United States

November 30, 2021; vol. 118 no. 48

<https://www.pnas.org/content/118/48>

[New issue; No digest content identified]

Prehospital & Disaster Medicine

Volume 36 - Issue 6 - December 2021

<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>

[Reviewed earlier]

Preventive Medicine

Volume 152, Part 2, November 2021

<https://www.sciencedirect.com/journal/preventive-medicine/vol/152/part/P2>

Behavior Change, Health, and Health Disparities 2021: Rural Addiction and Health

[Reviewed earlier]

Proceedings of the Royal Society B

08 December 2021 Volume 288 Issue 1964

<https://royalsocietypublishing.org/toc/rspb/current>

[New issue; No digest content identified]

Public Health

Volume 201 Pages 1-126 (December 2021)

<https://www.sciencedirect.com/journal/public-health/vol/201/suppl/C>

Review article Full text access

Development of a critical appraisal tool for models predicting the impact of 'test, trace, and protect' programmes on COVID-19 transmission

J.W. Frank, G. Marion, A. Doeschl-Wilson

Pages 55-60

Research article Full text access

Understanding and addressing vaccine hesitancy in the context of COVID-19: development of a digital intervention

H. Knight, R. Jia, K. Ayling, K. Bradbury, ... K. Vedhara

Pages 98-107

Public Health Ethics

Volume 14, Issue 3, November 2021

<http://phe.oxfordjournals.org/content/current>

Original Articles

The 'Ethical' COVID-19 Vaccine is the One that Preserves Lives: Religious and Moral Beliefs on the COVID-19 Vaccine

Alberto Giubilini, Francesca Minerva, Udo Schuklenk, Julian Savulescu

Public Health Ethics, Volume 14, Issue 3, November 2021, Pages 242–255,

<https://doi.org/10.1093/phe/phab018>

Public Health Reports

Volume 136 Issue 6, November/December 2021

<https://journals.sagepub.com/toc/phrg/136/6>

[Reviewed earlier]

Qualitative Health Research

Volume 31 Issue 14, December 2021

<https://journals.sagepub.com/toc/qhra/current>

[New issue; No digest content identified]

Research Ethics

Volume 18 Issue 1, January 2022

<http://journals.sagepub.com/toc/reab/current>

Topic Piece

[Reshaping the review of consent so we might improve participant choice](#)

Hugh Davies on behalf of the Oxford "A" Research Ethics Committee

First Published September 15, 2021; pp. 3–12

Reproductive Health

<http://www.reproductive-health-journal.com/content>

[Accessed 11 Dec 2021]

[No new digest content identified]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)

<https://www.paho.org/journal/en>

Selected Articles

10 Dec 2021

[Investigations of socioeconomic factors associated with follow-up compliance with malaria treatment in Haiti](#)

Original research | English |

10 Dec 2021

[Global control of COVID-19: good vaccines may not suffice](#)

Opinion and analysis | English |

Risk Analysis

Volume 41, Issue 11 Pages: 1957-2176 November 2021

<https://onlinelibrary.wiley.com/toc/15396924/current>

[New issue; No digest content identified]

Risk Management and Healthcare Policy

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>

[Accessed 11 Dec 2021]

Commentary

[The 2018–2020 Ebola Outbreak in the Democratic Republic of Congo: A Better Response Had Been Achieved Through Inter-State Coordination in Africa](#)

Guetiya Wadoum RE, Sevalie S, Minutolo A, Clarke A, Russo G, Colizzi V, Mattei M, Montesano C

Risk Management and Healthcare Policy [2021](#), 14:4923-4930
Published Date: 10 December 2021

Original Research

[Control and Prevention of the COVID-19 Epidemic in China: A Qualitative Community Case Study](#)

Wu Y, Zhang Q, Li L, Li M, Zuo Y

Risk Management and Healthcare Policy [2021](#), 14:4907-4922

Published Date: 9 December 2021

Science

Volume 374| Issue 6573| 10 Dec 2021

<https://www.science.org/toc/science/current>

Editorial

[Academic freedom under fire](#)

BY Jonathan R. Cole

09 Dec 2021: 1300-1300

Policy Forum

[Filling gaps in trustworthy development of AI](#)

BY Shahar Avin [...] Noa Zilberman

09 Dec 2021: 1327-1329

Incident sharing, auditing, and other concrete mechanisms could help verify the trustworthiness of actors

Research Articles

[Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccine–boosted nonhuman primates](#)

BY Kizzmekia S. Corbett, [...] Robert A. Seder

21 Oct 2021: 1343-1353

Open Access

COVID vaccine boosting should help to sustain protection against severe disease, reduce the frequency of infection, and limit transmission.

[Membrane fusion and immune evasion by the spike protein of SARS-CoV-2 Delta variant](#)

BY Jun Zhang [...] Bing Chen

26 Oct 2021: 1353-1360

Open Access

Structural and functional studies explain the heightened transmissibility and immune evasion of the SARS-CoV-2 Delta variant.

Science Translational Medicine

Volume 13| Issue 623| 8 Dec 2021

<https://www.science.org/toc/stm/current>

[New issue; No digest content identified]

Social Science & Medicine

Volume 289 November 2021

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/289/suppl/C>

[Reviewed earlier]

Systematic Reviews

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 11 Dec 2021]

[No new digest content identified]

Theoretical Medicine and Bioethics

Volume 42, issue 1-2, April 2021

<https://link.springer.com/journal/11017/volumes-and-issues/42-1>

[Reviewed earlier]

Travel Medicine and Infectious Diseases

Volume 44 November–December 2021

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/44/suppl/C>

[Reviewed earlier]

Tropical Medicine & International Health

Volume 26, Issue 12 Pages: i-iv, 1527-1717 December 2021

<https://onlinelibrary.wiley.com/toc/13653156/current>

[Reviewed earlier]

Vaccine

Volume 39, Issue 49 Pages 7117-7220 (3 December 2021)

<https://www.sciencedirect.com/journal/vaccine/vol/39/issue/49>

Discussion Full text access

[COVID-19 from a polio perspective](#)

Robert Hill

Pages 7117-7118

Discussion Full text access

[SARS-CoV-2 vaccine for domestic and captive animals: An effort to counter COVID-19 pandemic at the human-animal interface](#)

Khan Sharun, Ruchi Tiwari, AbdulRahman A. Saied, Kuldeep Dhama

Pages 7119-7122

Discussion Full text access

[The influence of interval between doses on response to vaccines](#)

Charlene M.C. Rodrigues, Stanley A. Plotkin

Pages 7123-7127

Discussion Full text access

[COVAX no fault compensation program for COVID-19 vaccine injuries in 92 low and middle income countries](#)

Anne Mazur, Stefanie Benitez, Stéphanie Chuffart-Finsterwald, Rafael La Rotta, Lee M. Hampton

Pages 7128-7130

Research article Full text access

[Social inequalities in COVID-19 vaccine acceptance and uptake for children and adolescents in Montreal, Canada](#)

Britt McKinnon, Caroline Quach, Ève Dubé, Cat Tuong Nguyen, Kate Zinszer

Pages 7140-7145

Research article Abstract only

[Mandatory immunization and vaccine injury support programs: A survey of 28 GNN countries](#)

Shawn H.E. Harmon, David E. Faour, Noni E. MacDonald

Pages 7153-7157

Advancing vaccine-product innovations for LMICs: Updates from the Vaccine Innovation Prioritisation Strategy (VIPS)

Discussion Full text access

[A global collaboration to advance vaccine product innovations – The Vaccine Innovation Prioritisation Strategy](#)

Debra Kristensen, Birgitte Giersing, Julian Hickling, Fatima Kazi, ... Marion Menozzi-Arnaud

Pages 7191-7194

Research article Open access

[Vaccine innovation prioritisation strategy: Findings from three country-stakeholder consultations on vaccine product innovations](#)

Mercy Mvundura, Collrane Frivold, Anna Janik Osborne, Priyanka Soni, ... Debra Kristensen

Pages 7195-7207

Review article Open access

[Strategies for vaccine-product innovation: Creating an enabling environment for product development to uptake in low- and middle-income countries](#)

Birgitte Giersing, Natasha Shah, Debra Kristensen, Jean-Pierre Amorij, ... Marion Menozzi-Arnaud

Pages 7208-7219

Value in Health

December 2021 Volume 24 Issue 12 p1715-1870

<https://www.valueinhealthjournal.com/current>

[Reviewed earlier]

::::::

::::::

Pre-Print Servers

Gates Open Research

<https://gatesopenresearch.org/browse/articles>

[Accessed 11 Dec 2021]

Research Article metrics AWAITING PEER REVIEW

Do differentiated service delivery models for HIV treatment in sub-Saharan Africa save money? Synthesis of evidence from field studies conducted in sub-Saharan Africa in 2017-2019 [version 1; peer review: awaiting peer review]

Sydney Rosen, Brooke Nichols, Teresa Guthrie, Mariet Benade, Salome Kuchukhidze, Lawrence Long

Peer Reviewers Invited

Funder - NIH

PUBLISHED 08 Dec 2021

medRxiv

<https://www.medrxiv.org/content/about-medrxiv>

medRxiv is a free online archive and distribution server for complete but unpublished manuscripts (preprints) in the medical, clinical, and related health sciences. Preprints are preliminary reports of work that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

medRxiv is for the distribution of preprints - complete but unpublished manuscripts - that describe human health research conducted, analyzed, and interpreted according to scientific principles...

[Accessed 11 Dec 2021]

Selected Content

SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection

Sandile Cele, Laurelle Jackson, Khadija Khan, David S Khoury, Thandeka Moyo-Gwete, Hourriyah Tegally, Cathrine Scheepers, Daniel Amoako, Farina Karim, Mallory Bernstein, Gila Lustig, Derseree Archary, Muneerah Smith, Yashica Ganga, Zesuliwe Jule, Kajal Reedoy, James Emmanuel San, Shi-Hsia Hwa, Jennifer Giandhari, Jonathan Blackburn, Bernadett I Gosnell, Salim Abdool Karim, Willem Hanekom, NGS-SA, COMMIT-KZN Team, Anne von Gottberg, Jinal Bhiman, Richard Lessells, Mahomed-Yunus S Moosa, Miles Philip Davenport, Tulio de Oliveira, Penny L. Moore, Alex Sigal
medRxiv 2021.12.08.21267417; doi: <https://doi.org/10.1101/2021.12.08.21267417>

The prevalence of adaptive immunity to COVID-19 and reinfection after recovery, a comprehensive systematic review and meta-analysis

Tawanda Chivese, Joshua Matizanadzo, Omran Musa, George Hindy, Luis Furuya-Kanamori, Nazmul Islam, Rafal Al-Shebly, Rana Shalaby, Mohammad Habibullah, Talal Al-Marwani, Rizeq F Hourani, Ahmed D Nawaz, Mohammad Haider, Mohamed M Emara, Farhan Cyprian, Suhail A. R. Doi
medRxiv 2021.09.03.21263103; doi: <https://doi.org/10.1101/2021.09.03.21263103>

Screening and vaccination against COVID-19 to minimize school closure

Elisabetta Colosi, Giulia Bassignana, Diego A Contreras, Canelle Poirier, Pierre-Yves Boëumille, Simon Cauchemez, Yazdan Yazdanpanah, Bruno Lina, Arnaud Fontanet, Alain Barrat, Vittoria Colizza
medRxiv 2021.08.15.21261243; doi: <https://doi.org/10.1101/2021.08.15.21261243>

Estimates of reduced vaccine effectiveness against hospitalization, infection, transmission and symptomatic disease of a new SARS-CoV-2 variant, Omicron (B.1.1.529), using neutralizing antibody titers

Billy J Gardner, A. Marm Kilpatrick

medRxiv 2021.12.10.21267594; doi: <https://doi.org/10.1101/2021.12.10.21267594>

Knowledge, attitudes, and practices (KAP) towards COVID-19: A quick online cross-sectional survey among Tanzanian residents.

sima rugarabamu, Aisha Byanaku, Mariam Ibrahim

medRxiv 2020.04.26.20080820; doi: <https://doi.org/10.1101/2020.04.26.20080820>

Surveillance of COVID-19 vaccine effectiveness – a real-time case-control study in southern Sweden

Jonas Björk, Carl Bonander, Mahnaz Moghaddassi, Magnus Rasmussen, Ulf Malmqvist, Fredrik Kahn, Malin Inghammar

medRxiv 2021.12.09.21267515; doi: <https://doi.org/10.1101/2021.12.09.21267515>

Trust in the research community predicts intent to comply with COVID-19 prevention measures: An analysis of a large-scale international survey dataset

Hyemin Han

medRxiv 2021.12.08.21267486; doi: <https://doi.org/10.1101/2021.12.08.21267486>

Vaccine hesitancy for COVID-19 explored in a phenomic study of 259 socio-cognitive-behavioural measures in the UK-REACH study of 12,431 UK healthcare workers

I Chris McManus, Katherine Woolf, Christopher A Martin, Laura B Nellums, Anna L Guyatt, Carl Melbourne, Luke Bryant, Amit Gupta, Catherine John, Martin D Tobin, Sue Carr, Sandra Simpson, Bindu Gregary, Avinash Aujayeb, Stephen Zingwe, Rubina Reza, Laura J Gray, Kamlesh Khunti, Manish Pareek
medRxiv 2021.12.08.21267421; doi: <https://doi.org/10.1101/2021.12.08.21267421>

Vaccine hesitancy for COVID-19 explored in a phenomic study of 259 socio-cognitive-behavioural measures in the UK-REACH study of 12,431 UK healthcare workers

I Chris McManus, Katherine Woolf, Christopher A Martin, Laura B Nellums, Anna L Guyatt, Carl Melbourne, Luke Bryant, Amit Gupta, Catherine John, Martin D Tobin, Sue Carr, Sandra Simpson, Bindu Gregary, Avinash Aujayeb, Stephen Zingwe, Rubina Reza, Laura J Gray, Kamlesh Khunti, Manish Pareek
medRxiv 2021.12.08.21267421; doi: <https://doi.org/10.1101/2021.12.08.21267421>

Global disparities in SARS-CoV-2 genomic surveillance

Anderson F. Brito, Elizaveta Semenova, Gytis Dudas, Gabriel W. Hassler, Chaney C. Kalinich, Moritz U.G. Kraemer, Joses Ho, Houriiyah Tegally, George Githinji, Charles N. Agoti, Lucy E. Matkin, Charles Whittaker, Danish Covid-19 Genome Consortium, COVID-19 Impact Project, Network for Genomic Surveillance in South Africa (NGS-SA), GISAID core curation team, Benjamin P Howden, Vitali Sintchenko, Neta S. Zuckerman, Orna Mor, Heather M Blankenship, Tulio de Oliveira, Raymond T. P. Lin, Marilda Mendonça Siqueira, Paola Cristina Resende, Ana Tereza R. Vasconcelos, Fernando R. Spilki, Renato Santana Aguiar, Ivailo Alexiev, Ivan N. Ivanov, Ivva Philipova, Christine V. F. Carrington, Nikita S. D. Sahadeo, Céline Gurry, Sebastian Maurer-Stroh, Dhamari Naidoo, Karin J von Eije, Mark D. Perkins, Maria van Kerkhove, Sarah C. Hill, Ester C. Sabino, Oliver G. Pybus, Christopher Dye, Samir Bhatt, Seth Flaxman, Marc A. Suchard, Nathan D. Grubaugh, Guy Baele, Nuno R. Faria
medRxiv 2021.08.21.21262393; doi: <https://doi.org/10.1101/2021.08.21.21262393>

Abstract

Genomic sequencing provides critical information to track the evolution and spread of SARS-CoV-2, optimize molecular tests, treatments and vaccines, and guide public health responses. To investigate the spatiotemporal heterogeneity in the global SARS-CoV-2 genomic surveillance, we estimated the impact of sequencing intensity and turnaround times (TAT) on variant detection in 167 countries. Most countries submit genomes >21 days after sample collection, and 77% of low and middle income countries sequenced <0.5% of their cases. We found that sequencing at least 0.5% of the cases, with a TAT <21 days, could be a benchmark for SARS-CoV-2 genomic surveillance efforts. Socioeconomic inequalities substantially impact our ability to quickly detect SARS-CoV-2 variants, and undermine the global pandemic preparedness.

The challenge of limited vaccine supplies: impact of prior infection on anti-spike IgG antibody trajectories after a single COVID-19 vaccination

Jia Wei, Philippa C. Matthews, Nicole Stoesser, Ian Diamond, Ruth Studley, Emma Rourke, Duncan Cook, John I Bell, John N Newton, Jeremy Farrar, Alison Howarth, Brian D. Marsden, Sarah Hoosdally, E Yvonne Jones, David I Stuart, Derrick W. Crook, Tim E. A. Peto, A. Sarah Walker, David W. Eyre, Koen B. Pouwels, the COVID-19 Infection Survey team

medRxiv 2021.12.08.21267353; doi: <https://doi.org/10.1101/2021.12.08.21267353>

Long COVID Citizen Scientists – Developing a needs-based research agenda by persons affected by Long COVID

Sarah Ziegler, Alessia Raineri, Vasileios Nittas, Natalie Rangelov, Fabian Vollrath, Chantal Britt, Milo A Puhan

medRxiv 2021.12.08.21267181; doi: <https://doi.org/10.1101/2021.12.08.21267181>

COVID-19 Vaccination Mandates and Vaccine Uptake

Alexander Karaivanov, Dongwoo Kim, Shih En Lu, Hitoshi Shigeoka

medRxiv 2021.10.21.21265355; doi: <https://doi.org/10.1101/2021.10.21.21265355>

Abstract

We evaluate the impact of government mandated proof of vaccination requirements for access to public venues and non-essential businesses on COVID-19 vaccine uptake. We find that the announcement of a mandate is associated with a rapid and significant surge in new vaccinations (more than 60% increase in weekly first doses) using the variation in the timing of these measures across Canadian provinces in a difference-in-differences approach. Time-series analysis for each province and for France, Italy and Germany corroborates this finding, and we estimate cumulative gains of up to 5 percentage points in provincial vaccination rates and 790,000 or more first doses for Canada as a whole as of October 31, 2021 (5 to 13 weeks after the provincial mandate announcements). We also find large vaccination gains in France (3 to 5 mln first doses), Italy (around 6 mln) and Germany (around 3.5 mln) 11 to 16 weeks after the proof of vaccination mandate announcements.

COVID-19 infections post-vaccination by HIV status in the United States

Sally B. Coburn, Elizabeth Humes, Raynell Lang, Cameron Stewart, Brenna C Hogan, Kelly A. Gebo, Sonia Napravnik, Jessie K. Edwards, Lindsay E. Browne, Lesley S. Park, Amy C. Justice, Kirsha Gordon, Michael A. Horberg, Julia M. Certa, Eric Watson, Celeena R Jefferson, Michael Silverberg, Jacek Skarbinski, Wendy A Leyden, Carolyn F. Williams, Keri N. Althoff, for the Corona-Infectious-Virus Epidemiology Team (CIVETs) of the NA-ACCORD of IeDEA

medRxiv 2021.12.02.21267182; doi: <https://doi.org/10.1101/2021.12.02.21267182>

Wellcome Open Research [to 11 Dec 2021]
<https://wellcomeopenresearch.org/browse/articles>
[Accessed 11 Dec 2021]

Wellcome Open Research provides all Wellcome researchers with a place to rapidly publish any results they think are worth sharing. All articles benefit from rapid publication, transparent peer review and editorial guidance on making all source data openly available.

Research Article metrics

Revised

[Estimating the number of undetected COVID-19 cases among travellers from mainland](#)

[China](#) [version 3; peer review: 3 approved]

Sangeeta Bhatia, Natsuko Imai, Gina Cuomo-Dannenburg, Marc Baguelin, Adhiratha Boonyasiri, Anne Cori, Zulma Cucunubá, Ilaria Dorigatti, Rich FitzJohn, Han Fu, Katy Gaythorpe, Azra Ghani, Arran Hamlet, Wes Hinsley, Daniel Laydon, Gemma Nedjati-Gilani, Lucy Okell, Steven Riley, Hayley Thompson, Sabine van Elsland, Erik Volz, Haowei Wang, Yuanrong Wang, Charles Whittaker, Xiaoyue Xi, Christl A. Donnelly, Neil M. Ferguson

Peer Reviewers Jeremy Bingham and Juliet R.C. Pulliam; Sebastian Funk; Hannah E. Clapham

Funders

Wellcome Trust

European and Developing Countries Clinical Trials Partnership

National Institute for Health Research

Department for International Development, UK Government

Medical Research Council

LATEST VERSION PUBLISHED 06 Dec 2021

* * * *

Think Tanks

Brookings [to 11 Dec 2021]
<http://www.brookings.edu/>

Accessed 11 Dec 2021

Up Front

[What we can learn from Israel's COVID-19 vaccination of children](#)

Oren Heller, Yaniv Shlomo, and Michal Grinstein-Weiss

Friday, December 10, 2021

A study conducted by the Social Policy Institute at Washington University in St. Louis shows that among surveyed parents in Israel, only 37 percent intended to vaccinate their child (aged 5-11) against COVID-19 when the option became available, while 23 percent of parents were undecided and 40 percent had no intention to vaccinate their children.

The study was conducted November 3-8, 2021, among a representative sample of Israeli parents of children aged 5-11 (N = 912)...

Center for Global Development [to 11 Dec 2021]
<http://www.cgdev.org/page/press-center>

Accessed 11 Dec 2021

Applications of Machine Learning and Advanced Analytics in Pandemic Preparedness and Response: Translating Models into Policy Action

Event

12/15/21

The Updated International Health Regulations Need Better Rules for Travel Restrictions

December 9, 2021

The last week has demonstrated the level of security theatre that has often been involved with travel bans put in place to reduce the spread of COVID-19. But heavy travel restrictions have played a role in the strategies of some of the countries that have most successfully battled the pandemic. As part of an effort to strengthen the International Health Regulations, the World Health Organization (WHO) should propose approaches that will limit travel restrictions to where they are most likely to be effective and design them to be minimally disruptive.

Charles Kenny

We Should Prepare for an Omicron COVID-19 Wave by Prioritising Cost-Effective Essential Emergency Critical Care Now

December 6, 2021

Hiral Anil Shah et al.

Chatham House [to 11 Dec 2021]

<https://www.chathamhouse.org/>

Accessed 11 Dec 2021

Covid's solidarity failure

Pledges of 'vaccines for everyone' may have gone unfulfilled but the case for universal health reforms is gaining ground, writes Rob Yates

The World Today

3 December 2021

CSIS

<https://www.csis.org/>

Accessed 11 Dec 2021

Upcoming Event

The Road to the 2022 Summit of the Americas: Vaccine Diplomacy and Engagement

December 14, 2021

Kaiser Family Foundation

https://www.kff.org/search/?post_type=press-release

Accessed 11 Dec 2021

December 10, 2021 *News Release*

Health Employment Continues Slow Recovery Since the Beginning of the Pandemic

Unlike past recessions, the health sector saw a big drop in employment in early 2020 similar to other sectors as the COVID-19 pandemic shut down much of the nation's economy and remains below

expected employment levels through November 2021, a new KFF chart collection shows. The chart collection takes a...

December 9, 2021 *News Release*

Half of Parents of Adolescents 12-17 Say Their Child Has Gotten a COVID-19 Vaccine, though Uptake Has Slowed; 16% of Parents of 5-11 Year-olds Say Their Child Has Gotten a Vaccine

COVID-19 vaccine uptake among adolescents ages 12-17 has slowed after an initial wave of enthusiasm over the summer, with half (49%) of parents saying their adolescent has received at least one dose, a new KFF COVID-19 Vaccine Monitor report reveals. The share is little changed since earlier in the fall....

December 8, 2021 *News Release*

Following an Early Period of High Demand, Vaccination for Children Ages 5-11 Has Significantly Slowed

As of December 5, 16.7% of 5-11 year-olds had received at least one COVID-19 vaccine dose with 4.3% of children reaching full vaccination, according to a new KFF analysis. After a short period of high demand, the rate of new vaccinations slowed significantly leading into the Thanksgiving holiday and has...

ODI [Overseas Development Institute] [to 11 Dec 2021]

<https://odi.org/en/publications/>

Publications

[No new digest content identified]

* * * *

Contents [click to move among sections]

- :: [Milestones - Perspectives](#)
- :: [Coronavirus \[COVID-19\] - WHO](#)
- :: [Emergencies](#)
- :: [Organization Announcements](#)
- :: [Journal Watch](#)

* * * *

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy (CVEP)/GE2P2 Global Foundation, which is solely responsible for its content.

::::::

Copyright GE2P2 Global Foundation 2021. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation The Rockefeller foundation, Boston University, or 3-D Commission logos is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

:::::::

CVEP is a program of the GE2P2 Global Foundation whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the Bill & Melinda Gates Foundation; the Bill & Melinda Gates Medical Research Institute , PATH, and industry resource members Janssen/J&J, Pfizer and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

* * * *